belinostat - Ontology Report - Rat Genome Database

Submit Data | Help | Video Tutorials | News | Publications | Download | REST API | Citing RGD | Contact

Advanced Search (OLGA)

CHEBI ONTOLOGY - ANNOTATIONS

{{ watchLinkText }}

The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.

Term:	belinostat	go back to main search page
Accession:	CHEBI:61076	browse the term
Definition:	A hydroxamic acid-type histone deacetylase (HDAC) inhibitor with antineoplastic activity.
Synonyms:	exact_synonym:	(2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]prop-2-enamide
	related_synonym:	(2E)-N-hydroxy-3-[3-(phenylsulfamoyl)phenyl]acrylamide; Formula=C15H14N2O4S; InChI=1S/C15H14N2O4S/c18-15(16-19)10-9-12-5-4-8-14(11-12)22(20,21)17-13-6-2-1-3-7-13/h1-11,17,19H,(H,16,18)/b10-9+; InChIKey=NCNRHFGMJRPRSK-MDZDMXLPSA-N; N-Hydroxy-3-(3-(phenylsulfamoyl)phenyl)prop-2-enamide; PXD101; SMILES=ONC(=O)\\C=C\\c1cccc(c1)S(=O)(=O)Nc1ccccc1
	xref:	CAS:414864-00-9; KEGG:D08870
	xref_mesh:	MESH:C487081
	xref:	PMID:23382909; PMID:23475695; PMID:23644904; PMID:24020452; PMID:24369094; PMID:24800886; PMID:24918834; PMID:25134672; PMID:25189481; PMID:25368524; PMID:25389633; PMID:25404094; PMID:25433307; PMID:25446119; PMID:25483416; PMID:25611313; PMID:25673888; Reaxys:10087570; Wikipedia:Belinostat

show annotations for term's descendants Sort by:
Rat (654 ) Mouse (659 ) Human (701 ) Chinchilla (0 ) Bonobo (0 ) Dog (0 ) Squirrel (0 ) Pig (0 ) Green Monkey (0) Naked Mole-rat (0 ) All
Genes (654)

term browser

Symbol

Object Name

Qualifiers

Evidence

Notes

Source

PubMed Reference(s)

RGD Reference(s)

Position

G

ATP binding cassette subfamily C member 6

decreases expression

ISO

belinostat results in decreased expression of ABCC6 mRNA

NCBI chr 1:105,583,681...105,637,895
Ensembl chr 1:105,583,682...105,637,895

G

ABL proto-oncogene 1, non-receptor tyrosine kinase

decreases expression

ISO

belinostat results in decreased expression of ABL1 mRNA

NCBI chr 3:35,377,587...35,480,843
Ensembl chr 3:35,377,391...35,480,846

G

acetyl-CoA carboxylase beta

decreases expression

ISO

belinostat results in decreased expression of ACACB mRNA

NCBI chr12:42,365,800...42,477,651
Ensembl chr12:48,026,394...48,138,214

G

acyl-CoA dehydrogenase, short/branched chain

increases expression

ISO

belinostat results in increased expression of ACADSB mRNA

NCBI chr 1:186,188,939...186,227,796
Ensembl chr 1:195,619,038...195,660,561

G

atypical chemokine receptor 3

increases expression

ISO

belinostat results in increased expression of ACKR3 mRNA

NCBI chr 9:90,799,682...90,811,246
Ensembl chr 9:98,246,605...98,260,214

G

acid phosphatase 5, tartrate resistant

decreases expression

ISO

belinostat results in decreased expression of ACP5 mRNA

NCBI chr 8:20,663,984...20,670,604
Ensembl chr 8:28,939,985...28,943,929

G

acyl-CoA synthetase long-chain family member 5

decreases expression

ISO

belinostat results in decreased expression of ACSL5 mRNA

NCBI chr 1:254,289,513...254,336,608
Ensembl chr 1:264,294,864...264,341,943

G

acyl-CoA synthetase medium-chain family member 3

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSM3 mRNA

NCBI chr 1:174,133,260...174,159,966
Ensembl chr 1:183,564,635...183,591,437

G

adenosine deaminase

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of ADA mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:172,818,174...172,842,283
Ensembl chr 3:172,818,176...172,842,293

G

ADAM metallopeptidase domain 12

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of ADAM12 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM12 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:188,686,984...189,014,206
Ensembl chr 1:198,116,975...198,447,552

G

ADAM metallopeptidase with thrombospondin type 1 motif, 15

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS15 mRNA

NCBI chr 8:29,307,864...29,331,249
Ensembl chr 8:37,566,065...37,589,446

G

ADAM metallopeptidase with thrombospondin type 1, motif 3

decreases expression

ISO

belinostat results in decreased expression of ADAMTS3 mRNA

NCBI chr14:18,231,128...18,437,771
Ensembl chr14:18,515,249...18,721,887

G

adenylate cyclase activating polypeptide 1

increases expression
multiple interactions

ISO

belinostat results in increased expression of ADCYAP1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:120,550,236...120,569,096
Ensembl chr 9:120,550,328...120,556,383

G

adhesion G protein-coupled receptor G1

multiple interactions
decreases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRG1 mRNA
belinostat results in decreased expression of ADGRG1 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:10,009,983...10,047,138
Ensembl chr19:10,010,031...10,047,124

G

adhesion G protein-coupled receptor L3

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of ADGRL3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:26,336,320...27,104,060
Ensembl chr14:26,722,194...27,280,418

G

acireductone dioxygenase 1

decreases expression

ISO

belinostat results in decreased expression of ADI1 mRNA

NCBI chr 6:45,306,885...45,313,847
Ensembl chr 6:51,034,931...51,042,855

G

alpha-fetoprotein

decreases expression

ISO

belinostat results in decreased expression of AFP mRNA

NCBI chr14:17,857,584...17,875,645
Ensembl chr14:17,857,584...17,875,649

G

adenylate kinase 7

increases expression

ISO

belinostat results in increased expression of AK7 mRNA

NCBI chr 6:124,611,789...124,679,978
Ensembl chr 6:130,376,550...130,444,677

G

AT-hook transcription factor

decreases expression

ISO

belinostat results in decreased expression of AKNA mRNA

NCBI chr 5:81,792,928...81,839,936
Ensembl chr 5:81,792,929...81,831,528

G

AKT serine/threonine kinase 1

increases phosphorylation

ISO

belinostat results in increased phosphorylation of AKT1 protein

NCBI chr 6:137,534,810...137,555,131
Ensembl chr 6:137,535,390...137,552,610

G

aldolase, fructose-bisphosphate B

decreases expression

ISO

belinostat results in decreased expression of ALDOB mRNA

NCBI chr 5:63,889,045...63,902,086
Ensembl chr 5:68,684,542...68,716,740

G

adenosine monophosphate deaminase 3

decreases expression

ISO

belinostat results in decreased expression of AMPD3 mRNA

NCBI chr 1:164,884,823...164,929,899
Ensembl chr 1:174,294,867...174,364,608

G

angiopoietin 1

increases expression
multiple interactions

ISO

belinostat results in increased expression of ANGPT1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:73,528,345...73,783,953
Ensembl chr 7:75,418,218...75,668,696

G

angiopoietin 2

decreases expression

ISO

belinostat results in decreased expression of ANGPT2 mRNA

NCBI chr16:71,088,364...71,138,805
Ensembl chr16:77,790,563...77,841,239

G

ankyrin repeat and sterile alpha motif domain containing 1B

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKS1B mRNA

NCBI chr 7:24,313,339...25,479,307
Ensembl chr 7:26,201,240...27,364,943

G

anoctamin 3

increases expression
multiple interactions

ISO

belinostat results in increased expression of ANO3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:97,235,671...97,550,090
Ensembl chr 3:117,692,103...118,004,675

G

annexin A2

increases expression
multiple interactions

ISO

belinostat results in increased expression of ANXA2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:78,986,252...79,022,638
Ensembl chr 8:78,986,242...79,022,631

G

annexin A4

decreases expression

ISO

belinostat results in decreased expression of ANXA4 mRNA

NCBI chr 4:119,184,378...119,241,183
Ensembl chr 4:120,741,750...120,798,513

G

aldehyde oxidase 1

decreases expression

ISO

belinostat results in decreased expression of AOX1 mRNA

NCBI chr 9:67,073,831...67,152,980
Ensembl chr 9:67,073,821...67,152,980

G

adaptor related protein complex 5 subunit mu 1

increases expression

ISO

belinostat results in increased expression of AP5M1 mRNA

NCBI chr15:22,355,478...22,385,222
Ensembl chr15:24,835,100...24,862,606

G

apelin receptor early endogenous ligand

increases expression

ISO

belinostat results in increased expression of APELA mRNA

NCBI chr16:24,694,356...24,703,466
Ensembl chr16:29,460,812...29,469,955

G

apolipoprotein C1

decreases expression

ISO

belinostat results in decreased expression of APOC1 mRNA

NCBI chr 1:88,475,018...88,479,052
Ensembl chr 1:88,474,663...88,478,155

G

ArfGAP with RhoGAP domain, ankyrin repeat and PH domain 3

decreases expression

ISO

belinostat results in decreased expression of ARAP3 mRNA

NCBI chr18:30,058,739...30,085,415
Ensembl chr18:30,058,275...30,084,865

G

Rho GTPase activating protein 24

increases expression
multiple interactions

ISO

belinostat results in increased expression of ARHGAP24 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP24 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:6,800,624...7,183,877
Ensembl chr14:7,105,200...7,528,950

G

Rho guanine nucleotide exchange factor 37

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of ARHGEF37 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGEF37 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:54,935,256...55,001,017
Ensembl chr18:57,230,117...57,271,031

G

Rho guanine nucleotide exchange factor 4

decreases expression

ISO

belinostat results in decreased expression of ARHGEF4 mRNA

NCBI chr 9:36,861,800...37,005,079
Ensembl chr 9:44,357,736...44,501,550

G

aryl hydrocarbon receptor nuclear translocator 2

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARNT2 mRNA

NCBI chr 1:138,236,235...138,392,868
Ensembl chr 1:147,599,058...147,801,997

G

arrestin, beta 1

increases expression
multiple interactions

ISO

belinostat results in increased expression of ARRB1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARRB1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:163,249,654...163,321,711
Ensembl chr 1:163,250,157...163,340,859

G

asialoglycoprotein receptor 1

decreases expression

ISO

belinostat results in decreased expression of ASGR1 mRNA

NCBI chr10:54,775,727...54,779,642
Ensembl chr10:55,274,706...55,278,322

G

asparagine synthetase (glutamine-hydrolyzing)

decreases expression

ISO

belinostat results in decreased expression of ASNS mRNA

NCBI chr 4:35,784,995...35,803,474
Ensembl chr 4:36,751,802...36,776,050

G

astrotactin 1

decreases expression

ISO

belinostat results in decreased expression of ASTN1 mRNA

NCBI chr13:70,537,423...70,855,440
Ensembl chr13:73,071,267...73,388,895

G

ATPase phospholipid transporting 8B1

increases expression
multiple interactions

ISO

belinostat results in increased expression of ATP8B1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B1 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:58,016,382...58,157,213
Ensembl chr18:60,288,464...60,427,027

G

aurora kinase A

decreases expression
decreases activity

ISO

belinostat results in decreased expression of AURKA mRNA; belinostat results in decreased expression of AURKA protein
belinostat results in decreased activity of AURKA protein

NCBI chr 3:181,546,742...181,562,890
Ensembl chr 3:181,546,742...181,562,771

G

aurora kinase B

decreases activity
decreases expression

ISO

belinostat results in decreased activity of AURKB protein
belinostat results in decreased expression of AURKB mRNA; belinostat results in decreased expression of AURKB protein

NCBI chr10:54,243,116...54,249,675
Ensembl chr10:54,242,850...54,252,285

G

apoptosis and caspase activation inhibitor

decreases expression

ISO

belinostat results in decreased expression of AVEN mRNA

NCBI chr 3:99,299,009...99,431,635
Ensembl chr 3:119,872,661...119,886,008

G

beta-1,3-N-acetylgalactosaminyltransferase 1 (globoside blood group)

decreases expression

ISO

belinostat results in decreased expression of B3GALNT1 mRNA

NCBI chr 2:153,847,297...153,877,371
Ensembl chr 2:156,156,265...156,188,404

G

UDP-GlcNAc:betaGal beta-1,3-N-acetylglucosaminyltransferase 5

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of B3GNT5 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B3GNT5 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:81,141,102...81,153,206
Ensembl chr11:94,645,480...94,660,514

G

BAG cochaperone 2

multiple interactions
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG2 mRNA
belinostat results in increased expression of BAG2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:35,970,033...35,980,677
Ensembl chr 9:43,465,995...43,476,752

G

BMP and activin membrane-bound inhibitor

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAMBI mRNA

NCBI chr17:54,121,251...54,125,816
Ensembl chr17:58,816,442...58,821,247

G

Bardet-Biedl syndrome 9

increases expression
multiple interactions

ISO

belinostat results in increased expression of BBS9 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BBS9 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:21,013,865...21,437,934
Ensembl chr 8:29,289,997...29,713,880

G

BCL11 transcription factor A

increases expression
multiple interactions

ISO

belinostat results in increased expression of BCL11A mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCL11A mRNA

PMID:26272509 PMID:27188386

NCBI chr14:102,230,147...102,325,289
Ensembl chr14:102,231,113...102,325,623

G

BCL2, apoptosis regulator

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of BCL2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:23,204,464...23,366,900
Ensembl chr13:23,204,464...23,366,900

G

Bcl2-like 11

increases expression

ISO

belinostat results in increased expression of BCL2L11 protein

NCBI chr 3:135,820,042...135,857,330
Ensembl chr 3:135,817,562...135,960,695

G

BCL2-associated transcription factor 1

decreases expression

ISO

belinostat results in decreased expression of BCLAF1 mRNA

NCBI chr 1:15,088,436...15,117,666
Ensembl chr 1:16,914,118...16,936,801

G

brain expressed X-linked 5 like 1

increases expression
multiple interactions

ISO

belinostat results in increased expression of BEX5 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEX5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:110,047,861...110,051,812

G

beaded filament structural protein 1

decreases expression

ISO

belinostat results in decreased expression of BFSP1 mRNA

NCBI chr 3:131,195,087...131,252,668
Ensembl chr 3:151,648,588...151,682,837

G

baculoviral IAP repeat-containing 5

decreases expression

ISO

belinostat results in decreased expression of BIRC5 mRNA

NCBI chr10:103,567,369...103,580,069
Ensembl chr10:103,572,080...103,582,155

G

bone morphogenetic protein 5

multiple interactions
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP5 mRNA
belinostat results in increased expression of BMP5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:76,517,164...76,639,925
Ensembl chr 8:85,396,925...85,520,189

G

BMP-binding endothelial regulator

increases expression
multiple interactions

ISO

belinostat results in increased expression of BMPER mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMPER mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:21,732,225...21,977,261
Ensembl chr 8:30,008,148...30,434,359

G

bone morphogenetic protein receptor type 1B

decreases expression

ISO

belinostat results in decreased expression of BMPR1B mRNA

NCBI chr 2:233,211,525...233,544,344
Ensembl chr 2:233,211,525...233,544,311

G

basonuclin zinc finger protein 2

multiple interactions
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNC2 mRNA
belinostat results in increased expression of BNC2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:98,679,071...99,016,044
Ensembl chr 5:103,724,934...104,125,428

G

BLOC-1 related complex subunit 8

increases expression
multiple interactions

ISO

belinostat results in increased expression of BORCS8 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BORCS8 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:19,274,305...19,280,969
Ensembl chr16:19,308,247...19,314,963

G

B-box and SPRY domain containing

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BSPRY mRNA

NCBI chr 5:75,927,397...75,949,585
Ensembl chr 5:80,942,979...80,988,154

G

similar to human chromosome 10 open reading frame 143

decreases expression

ISO

belinostat results in decreased expression of C10ORF143 mRNA

NCBI chr 1:192,184,440...192,222,676
Ensembl chr 1:201,561,396...201,652,127

G

similar to human chromosome 19 open reading frame 33

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C19ORF33 mRNA

NCBI chr 1:84,549,830...84,550,666
Ensembl chr 1:93,677,305...93,678,141

G

similar to human chromosome 4 open reading frame 33

increases expression

ISO

belinostat results in increased expression of C4ORF33 mRNA

NCBI chr 2:124,764,263...124,830,001
Ensembl chr 2:126,697,854...126,746,878

G

similar to human chromosome 11 open reading frame 96

increases expression
multiple interactions

ISO

belinostat results in increased expression of C11ORF96 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF96 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:79,920,125...79,921,368
Ensembl chr 3:100,351,199...100,378,346

G

similar to human chromosome 8 open reading frame 34

multiple interactions
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C8ORF34 mRNA
belinostat results in increased expression of C8ORF34 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:7,237,968...7,777,119
Ensembl chr 5:12,021,007...12,559,772

G

carbonic anhydrase 4

decreases expression

ISO

belinostat results in decreased expression of CA4 mRNA

NCBI chr10:70,325,102...70,333,916
Ensembl chr10:70,325,358...70,333,916

G

Cdk5 and Abl enzyme substrate 1

decreases expression

ISO

belinostat results in decreased expression of CABLES1 mRNA

NCBI chr18:3,076,556...3,181,181
Ensembl chr18:3,351,652...3,455,956

G

carbamoyl-phosphate synthetase 2, aspartate transcarbamylase, and dihydroorotase

decreases expression

ISO

belinostat results in decreased expression of CAD mRNA

NCBI chr 6:31,012,091...31,035,098
Ensembl chr 6:31,012,091...31,035,297

G

calbindin 1

increases expression

ISO

belinostat results in increased expression of CALB1 mRNA

NCBI chr 5:29,375,624...29,402,532
Ensembl chr 5:34,172,664...34,200,160

G

calcium homeostasis modulator family member 6

decreases expression

ISO

belinostat results in decreased expression of CALHM6 mRNA

NCBI chr20:26,095,591...26,097,336
Ensembl chr20:26,638,722...26,640,408

G

calmodulin-like 4

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of CALML4 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CALML4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:63,323,426...63,335,234
Ensembl chr 8:72,218,613...72,230,650

G

cell cycle associated protein 1

decreases expression

ISO

belinostat results in decreased expression of CAPRIN1 mRNA

NCBI chr 3:110,606,489...110,685,408
Ensembl chr 3:110,606,489...110,685,562

G

caspase recruitment domain family, member 10

decreases expression

ISO

belinostat results in decreased expression of CARD10 mRNA

NCBI chr 7:110,330,460...110,371,551
Ensembl chr 7:112,210,776...112,239,806

G

caspase 3

multiple interactions
increases cleavage

ISO

Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP3 protein]

NCBI chr16:52,395,539...52,413,794
Ensembl chr16:52,395,540...52,413,732

G

caspase 7

increases cleavage

ISO

belinostat results in increased cleavage of CASP7 protein

NCBI chr 1:255,437,438...255,476,737
Ensembl chr 1:265,442,676...265,482,512

G

caspase 8

increases expression
multiple interactions

ISO

belinostat results in increased expression of CASP8 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CASP8 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:60,263,863...60,312,542
Ensembl chr 9:67,758,033...67,806,699

G

caspase 9

increases cleavage
multiple interactions

ISO

belinostat results in increased cleavage of CASP9 protein
Bortezomib promotes the reaction [belinostat results in increased cleavage of CASP9 protein]

PMID:18223231 PMID:25537862

Ensembl chr 5:159,391,188...159,409,648

G

coiled-coil domain containing 34

increases expression

ISO

belinostat results in increased expression of CCDC34 mRNA

NCBI chr 3:96,553,074...96,588,310
Ensembl chr 3:117,005,760...117,042,226

G

coiled-coil domain containing 69

increases expression
multiple interactions

ISO

belinostat results in increased expression of CCDC69 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC69 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:39,173,282...39,200,358
Ensembl chr10:39,673,985...39,700,579

G

cholecystokinin B receptor

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of CCKBR mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCKBR mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:169,183,578...169,193,583
Ensembl chr 1:169,183,194...169,193,745

G

C-C motif chemokine ligand 26

increases expression
multiple interactions

ISO

belinostat results in increased expression of CCL26 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCL26 mRNA

PMID:26272509 PMID:27188386

NCBI chr12:26,745,972...26,750,924

G

cellular communication network factor 1

increases expression

ISO

belinostat results in increased expression of CCN1 mRNA

NCBI chr 2:237,222,730...237,225,689
Ensembl chr 2:237,222,432...237,225,883

G

cellular communication network factor 2

increases expression

ISO

belinostat results in increased expression of CCN2 mRNA

PMID:19606018 PMID:23671600

NCBI chr 1:22,621,498...22,624,614
Ensembl chr 1:22,621,501...22,624,976

G

cyclin A2

decreases expression

ISO

belinostat results in decreased expression of CCNA2 mRNA

NCBI chr 2:119,427,239...119,433,645
Ensembl chr 2:121,355,363...121,361,701

G

cyclin B1

decreases expression

ISO

belinostat results in decreased expression of CCNB1 mRNA

NCBI chr 2:33,646,252...33,655,225
Ensembl chr 2:33,646,252...33,655,225

G

cyclin D2

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of CCND2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCND2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:161,653,048...161,675,422
Ensembl chr 4:161,653,048...161,680,301
Ensembl chr 4:161,653,048...161,680,301

G

CD24 molecule

multiple interactions
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD24 mRNA
belinostat results in increased expression of CD24 mRNA

PMID:26272509 PMID:27188386

NCBI chr20:48,655,549...48,661,786
Ensembl chr20:48,655,805...48,661,785

G

CD9 molecule

increases expression
multiple interactions

ISO

belinostat results in increased expression of CD9 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD9 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:159,942,553...159,975,463
Ensembl chr 4:159,942,560...159,975,444

G

cell division cycle 25B

decreases expression

ISO

belinostat results in decreased expression of CDC25B mRNA

NCBI chr 3:138,860,148...138,870,287
Ensembl chr 3:138,860,130...138,870,492

G

cell division cycle 25C

decreases expression

ISO

belinostat results in decreased expression of CDC25C mRNA

NCBI chr18:26,335,156...26,356,199
Ensembl chr18:26,609,959...26,630,292

G

cadherin 1

increases expression
multiple interactions

ISO

belinostat results in increased expression of CDH1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH1 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:51,402,178...51,471,572
Ensembl chr19:51,402,034...51,471,565

G

cadherin 18

increases expression

ISO

belinostat results in increased expression of CDH18 mRNA

NCBI chr 2:72,818,076...73,820,144
Ensembl chr 2:75,075,595...75,550,720

G

cadherin 3

increases expression
multiple interactions

ISO

belinostat results in increased expression of CDH3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH3 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:34,393,596...34,444,084
Ensembl chr19:51,300,083...51,354,257

G

cadherin 9

decreases expression
increases expression

ISO

belinostat results in decreased expression of CDH9 mRNA
belinostat results in increased expression of CDH9 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:66,280,422...66,367,121
Ensembl chr 2:67,955,166...68,094,365

G

cyclin-dependent kinase 1

decreases expression

ISO

belinostat results in decreased expression of CDK1 mRNA

NCBI chr20:19,265,252...19,280,456
Ensembl chr20:19,265,289...19,280,455

G

cyclin-dependent kinase 4

decreases expression

ISO

belinostat results in decreased expression of CDK4 mRNA

NCBI chr 7:64,771,453...64,774,891
Ensembl chr 7:64,771,147...64,775,163

G

cyclin-dependent kinase inhibitor 1A

multiple interactions
increases expression

ISO

belinostat promotes the reaction [decitabine results in increased expression of CDKN1A mRNA]; belinostat promotes the reaction [decitabine results in increased expression of CDKN1A protein]
belinostat results in increased expression of CDKN1A mRNA; belinostat results in increased expression of CDKN1A protein

PMID:19234609 PMID:19606018

NCBI chr20:7,150,820...7,161,373
Ensembl chr20:7,153,958...7,164,969

G

cyclin-dependent kinase inhibitor 2A

decreases expression

ISO

belinostat results in decreased expression of CDKN2A mRNA

NCBI chr 5:109,100,763...109,114,448
Ensembl chr 5:109,100,772...109,119,248

G

caudal type homeo box 4

decreases expression

ISO

belinostat results in decreased expression of CDX4 mRNA

NCBI chr X:68,326,874...68,335,461
Ensembl chr X:72,392,653...72,401,239

G

centrosomal protein 126

increases expression
multiple interactions

ISO

belinostat results in increased expression of CEP126 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP126 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:13,485,211...13,552,711
Ensembl chr 8:13,490,685...13,552,221

G

centrosomal protein 85-like

increases expression
multiple interactions

ISO

belinostat results in increased expression of CEP85L mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP85L mRNA

PMID:26272509 PMID:27188386

NCBI chr20:32,568,417...32,739,449
Ensembl chr20:33,115,438...33,282,238

G

cilia and flagella associated protein 119

increases expression

ISO

belinostat results in increased expression of CFAP119 mRNA

NCBI chr 1:182,197,171...182,216,936
Ensembl chr 1:191,623,673...191,632,829

G

CFAP20 domain containing

increases expression

ISO

belinostat results in increased expression of CFAP20DC mRNA

NCBI chr15:16,231,248...16,476,978
Ensembl chr15:18,661,508...18,907,225

G

CF transmembrane conductance regulator

decreases expression

ISO

belinostat results in decreased expression of CFTR mRNA

NCBI chr 4:47,422,084...47,694,646
Ensembl chr 4:47,526,735...47,694,643

G

chromogranin A

increases expression
multiple interactions

ISO

belinostat results in increased expression of CHGA mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHGA mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:121,696,051...121,707,399
Ensembl chr 6:127,460,854...127,472,237

G

chondrolectin

multiple interactions
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHODL mRNA
belinostat results in increased expression of CHODL mRNA

PMID:26272509 PMID:27188386

NCBI chr11:17,654,137...17,676,450
Ensembl chr11:31,141,021...31,163,334

G

cholinergic receptor, muscarinic 3

increases expression
multiple interactions

ISO

belinostat results in increased expression of CHRM3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRM3 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:64,696,549...65,158,622
Ensembl chr17:64,696,066...65,173,304

G

cholinergic receptor nicotinic alpha 3 subunit

increases expression
multiple interactions

ISO

belinostat results in increased expression of CHRNA3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRNA3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:64,297,755...64,311,251
Ensembl chr 8:64,297,755...64,311,412

G

carbohydrate sulfotransferase 15

increases expression

ISO

belinostat results in increased expression of CHST15 mRNA

NCBI chr 1:187,028,860...187,107,908
Ensembl chr 1:196,460,425...196,491,444

G

ciliary microtubule associated protein 3

increases expression
multiple interactions

ISO

belinostat results in increased expression of CIMAP3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CIMAP3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:193,475,785...193,493,092
Ensembl chr 2:196,163,275...196,181,604

G

claudin 7

multiple interactions
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN7 mRNA
belinostat results in increased expression of CLDN7 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:55,188,670...55,190,871
Ensembl chr10:55,188,684...55,190,905

G

clarin 1

increases expression

ISO

belinostat results in increased expression of CLRN1 mRNA

NCBI chr 2:143,084,030...143,130,948
Ensembl chr 2:145,233,941...145,280,855

G

clarin 3

decreases expression

ISO

belinostat results in decreased expression of CLRN3 mRNA

NCBI chr 1:190,319,025...190,334,648
Ensembl chr 1:199,748,864...199,764,486

G

clusterin

multiple interactions
increases expression

ISO

belinostat promotes the reaction [decitabine results in increased expression of CLU mRNA]; belinostat promotes the reaction [decitabine results in increased expression of CLU protein]
belinostat results in increased expression of CLU mRNA; belinostat results in increased expression of CLU protein

PMID:19234609 PMID:19606018

NCBI chr15:44,336,619...44,375,861
Ensembl chr15:44,359,914...44,375,860

G

cytidine/uridine monophosphate kinase 2

decreases expression

ISO

belinostat results in decreased expression of CMPK2 mRNA

NCBI chr 6:43,073,706...43,085,183
Ensembl chr 6:48,802,321...48,813,652

G

connector enhancer of kinase suppressor of Ras 2

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA

NCBI chr X:36,908,135...37,148,337
Ensembl chr X:40,722,996...40,965,604

G

chondromodulin

increases expression
multiple interactions

ISO

belinostat results in increased expression of CNMD mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNMD mRNA

PMID:26272509 PMID:27188386

NCBI chr15:55,041,548...55,066,297
Ensembl chr15:61,450,450...61,475,350

G

contactin 1

increases expression
multiple interactions

ISO

belinostat results in increased expression of CNTN1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNTN1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:123,263,146...123,560,896
Ensembl chr 7:125,142,696...125,440,391

G

contactin 3

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of CNTN3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:134,841,268...135,214,460
Ensembl chr 4:136,398,572...136,770,717

G

contactin associated protein family member 4

decreases expression

ISO

belinostat results in decreased expression of CNTNAP4 mRNA

NCBI chr19:40,568,684...40,861,879
Ensembl chr19:57,477,310...57,821,701

G

cordon-bleu WH2 repeat protein

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBL mRNA

NCBI chr14:86,828,137...87,060,682
Ensembl chr14:91,041,721...91,274,257

G

cochlin

decreases expression

ISO

belinostat results in decreased expression of COCH mRNA

NCBI chr 6:74,766,485...74,780,504
Ensembl chr 6:74,766,419...74,780,502

G

collagen type I alpha 2 chain

multiple interactions
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A2 mRNA
belinostat results in increased expression of COL1A2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:33,518,557...33,553,484
Ensembl chr 4:33,518,420...33,553,995

G

collagen type XXVI alpha 1 chain

decreases expression

ISO

belinostat results in decreased expression of COL26A1 mRNA

NCBI chr12:19,792,693...19,938,556
Ensembl chr12:25,429,387...25,575,206

G

collagen type VI alpha 6 chain

decreases expression

ISO

belinostat results in decreased expression of COL6A6 mRNA

NCBI chr 8:106,318,010...106,473,419
Ensembl chr 8:115,197,464...115,352,136

G

collectin sub-family member 12

increases expression

ISO

belinostat results in increased expression of COLEC12 mRNA

NCBI chr18:732,950...920,620
Ensembl chr18:1,005,741...1,195,297

G

collagen beta(1-O)galactosyltransferase 2

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of COLGALT2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COLGALT2 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:64,523,641...64,628,295
Ensembl chr13:67,073,551...67,178,194

G

catechol-O-methyltransferase domain containing 1

multiple interactions
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COMTD1 mRNA
belinostat results in increased expression of COMTD1 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:2,459,783...2,462,895
Ensembl chr15:2,509,032...2,512,232

G

copine 2

decreases expression

ISO

belinostat results in decreased expression of CPNE2 mRNA

NCBI chr19:10,434,277...10,472,146
Ensembl chr19:10,434,647...10,477,783

G

copine 4

multiple interactions
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPNE4 mRNA
belinostat results in increased expression of CPNE4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:105,177,376...105,653,075
Ensembl chr 8:113,993,703...114,531,855

G

complement C3b/C4b receptor 1 like

increases expression
multiple interactions

ISO

belinostat results in increased expression of CR1L mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR1L mRNA

PMID:26272509 PMID:27188386

NCBI chr13:109,138,132...109,189,068
Ensembl chr13:109,103,235...109,188,869

G

crumbs cell polarity complex component 1

increases expression

ISO

belinostat results in increased expression of CRB1 mRNA

NCBI chr13:50,801,484...50,989,261
Ensembl chr13:53,352,932...53,540,019

G

cysteine rich protein 1

multiple interactions
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRIP1 mRNA
belinostat results in increased expression of CRIP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:132,226,746...132,234,620
Ensembl chr 6:138,047,801...138,055,672

G

cripto, EGF-CFC family member

increases expression

ISO

belinostat results in increased expression of CRIPTO mRNA

NCBI chr 8:119,803,182...119,808,714
Ensembl chr 8:119,803,220...119,808,948

G

crystallin, beta A4

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of CRYBA4 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA4 mRNA

PMID:26272509 PMID:27188386

NCBI chr12:44,378,734...44,393,226
Ensembl chr12:50,047,049...50,053,634

G

crystallin beta-gamma domain containing 1

increases expression
multiple interactions

ISO

belinostat results in increased expression of CRYBG1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRYBG1 mRNA

PMID:26272509 PMID:27188386

NCBI chr20:47,425,030...47,496,918
Ensembl chr20:49,007,929...49,204,047

G

collagen triple helix repeat containing 1

increases expression
multiple interactions

ISO

belinostat results in increased expression of CTHRC1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTHRC1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:72,007,372...72,017,654
Ensembl chr 7:72,007,372...72,017,654

G

CTP synthase 1

decreases expression

ISO

belinostat results in decreased expression of CTPS1 mRNA

NCBI chr 5:134,125,022...134,154,155
Ensembl chr 5:139,410,249...139,440,465

G

cathepsin K

decreases expression

ISO

belinostat results in decreased expression of CTSK mRNA

NCBI chr 2:185,747,548...185,758,512
Ensembl chr 2:185,747,165...185,765,582

G

cathepsin O

decreases expression

ISO

belinostat results in decreased expression of CTSO mRNA

NCBI chr 2:167,230,407...167,254,761
Ensembl chr 2:169,528,511...169,554,995

G

C-X-C motif chemokine ligand 12

increases expression
decreases expression
multiple interactions

ISO

belinostat results in increased expression of CXCL12 mRNA
belinostat results in decreased expression of CXCL12 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL12 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:152,060,781...152,073,628
Ensembl chr 4:152,060,780...152,073,627

G

C-X-C motif chemokine ligand 14

increases expression

ISO

belinostat results in increased expression of CXCL14 mRNA

NCBI chr17:8,323,150...8,331,176
Ensembl chr17:8,323,143...8,331,172

G

cytoplasmic FMR1 interacting protein 1

decreases expression

ISO

belinostat results in decreased expression of CYFIP1 mRNA

NCBI chr 1:115,842,754...115,935,163
Ensembl chr 1:115,846,661...115,951,292

G

cytochrome P450, family 1, subfamily b, polypeptide 1

increases expression

ISO

belinostat results in increased expression of CYP1B1 mRNA

NCBI chr 6:21,093,927...21,103,091
Ensembl chr 6:21,078,146...21,103,142

G

cytochrome P450, family 26, subfamily a, polypeptide 1

increases expression

ISO

belinostat results in increased expression of CYP26A1 mRNA

NCBI chr 1:244,883,822...244,887,657
Ensembl chr 1:244,883,752...244,887,657

G

cytochrome P450, family 39, subfamily a, polypeptide 1

increases expression

ISO

belinostat results in increased expression of CYP39A1 mRNA

NCBI chr 9:17,230,455...17,306,775
Ensembl chr 9:24,727,817...24,804,060

G

cytohesin 1

decreases expression

ISO

belinostat results in decreased expression of CYTH1 mRNA

NCBI chr10:103,402,727...103,485,826
Ensembl chr10:103,864,804...103,984,383

G

RIKEN cDNA D430041D05 gene like

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of KIAA1549L mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIAA1549L mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:90,506,559...90,782,427
Ensembl chr 3:110,961,478...111,237,223

G

dishevelled-binding antagonist of beta-catenin 1

increases expression
multiple interactions

ISO

belinostat results in increased expression of DACT1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACT1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:89,790,676...89,818,254
Ensembl chr 6:95,526,690...95,551,053

G

deleted in azoospermia-like

multiple interactions
decreases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAZL mRNA
belinostat results in decreased expression of DAZL mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:18,193,363...18,210,100
Ensembl chr 9:18,193,363...18,210,100

G

DDB1 and CUL4 associated factor 7

increases expression

ISO

belinostat results in increased expression of DCAF7 mRNA

NCBI chr10:90,974,095...90,996,275
Ensembl chr10:91,473,900...91,496,080

G

DCC netrin 1 receptor

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCC mRNA

NCBI chr18:67,144,272...68,248,159
Ensembl chr18:67,149,179...68,247,541

G

doublecortin domain containing 2

decreases expression

ISO

belinostat results in decreased expression of DCDC2 mRNA

NCBI chr17:40,274,009...40,459,757
Ensembl chr17:40,274,009...40,458,790

G

damage specific DNA binding protein 2

decreases expression

ISO

belinostat results in decreased expression of DDB2 mRNA

NCBI chr 3:77,185,114...77,207,650
Ensembl chr 3:97,640,579...97,664,066

G

dopa decarboxylase

decreases expression

ISO

belinostat results in decreased expression of DDC mRNA

NCBI chr14:90,592,304...90,682,830
Ensembl chr14:90,592,304...90,682,806

G

DExD-box helicase 21

decreases expression

ISO

belinostat results in decreased expression of DDX21 mRNA

NCBI chr20:30,534,319...30,554,513
Ensembl chr20:31,077,045...31,097,238

G

defensin beta 1

decreases expression

ISO

belinostat results in decreased expression of DEFB1 mRNA

NCBI chr16:77,001,326...77,016,068
Ensembl chr16:77,001,326...77,016,068

G

DENN domain containing 1A

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of DENND1A mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1A mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:21,564,749...22,052,057
Ensembl chr 3:41,974,502...42,461,886

G

DEP domain containing 7

increases expression
multiple interactions

ISO

belinostat results in increased expression of DEPDC7 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPDC7 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:91,099,111...91,121,152
Ensembl chr 3:111,554,706...111,575,979

G

DEP domain containing MTOR-interacting protein

increases expression
multiple interactions

ISO

belinostat results in increased expression of DEPTOR mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPTOR mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:88,404,745...88,574,065
Ensembl chr 7:88,404,620...88,574,041

G

diacylglycerol kinase, iota

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKI mRNA

NCBI chr 4:65,410,878...65,872,733
Ensembl chr 4:66,387,126...66,990,832

G

dehydrogenase/reductase 2

multiple interactions
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DHRS2 mRNA
belinostat results in increased expression of DHRS2 mRNA

PMID:19606018 PMID:27188386

NCBI chr15:32,658,855...32,673,591
Ensembl chr15:32,659,223...32,673,588

G

diaphanous-related formin 2

increases expression
multiple interactions

ISO

belinostat results in increased expression of DIAPH2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DIAPH2 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:92,395,189...93,234,521
Ensembl chr X:96,700,726...97,528,080

G

iodothyronine deiodinase 1

decreases expression

ISO

belinostat results in decreased expression of DIO1 mRNA

NCBI chr 5:127,303,089...127,319,784
Ensembl chr 5:127,303,083...127,319,771

G

dickkopf WNT signaling pathway inhibitor 1

increases expression

ISO

belinostat results in increased expression of DKK1 mRNA

NCBI chr 1:237,794,969...237,798,650
Ensembl chr 1:237,794,969...237,798,650

G

DnaJ heat shock protein family (Hsp40) member B1

increases expression

ISO

belinostat results in increased expression of DNAJB1 mRNA

NCBI chr19:41,427,453...41,431,141
Ensembl chr19:41,427,453...41,431,416

G

delta/notch-like EGF repeat containing

increases expression
multiple interactions

ISO

belinostat results in increased expression of DNER mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNER mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:85,586,985...85,902,461
Ensembl chr 9:93,035,108...93,350,568

G

dedicator of cytokinesis 10

decreases expression

ISO

belinostat results in decreased expression of DOCK10 mRNA

NCBI chr 9:81,843,599...82,101,540
Ensembl chr 9:89,291,800...89,549,973

G

docking protein 5

increases expression

ISO

belinostat results in increased expression of DOK5 mRNA

NCBI chr 3:159,515,886...159,652,811
Ensembl chr 3:179,934,552...180,071,333

G

developmental pluripotency-associated 2

increases expression
multiple interactions

ISO

belinostat results in increased expression of DPPA2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPPA2 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:52,549,024...52,556,740
Ensembl chr11:66,011,628...66,020,994

G

developmental pluripotency associated 5

increases expression
multiple interactions

ISO

belinostat results in increased expression of DPPA5 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPPA5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:79,215,341...79,217,282
Ensembl chr 1:14,260,684...14,261,146

G

deltex E3 ubiquitin ligase 3L

decreases expression

ISO

belinostat results in decreased expression of DTX3L mRNA

NCBI chr11:64,814,926...64,824,539
Ensembl chr11:78,317,650...78,329,837

G

dual specificity phosphatase 10

increases expression

ISO

belinostat results in increased expression of DUSP10 mRNA

NCBI chr13:95,613,716...95,651,716
Ensembl chr13:98,145,893...98,183,304

G

dual specificity phosphatase 9

decreases expression

ISO

belinostat results in decreased expression of DUSP9 mRNA

NCBI chr X:151,351,897...151,355,822
Ensembl chr X:156,503,190...156,507,161

G

dynein light chain Tctex-type family member 5

increases expression

ISO

belinostat results in increased expression of DYNLT5 mRNA

NCBI chr 5:117,735,509...117,758,221
Ensembl chr 5:122,964,845...122,987,304

G

E2F transcription factor 2

decreases expression

ISO

belinostat results in decreased expression of E2F2 mRNA

NCBI chr 5:153,682,789...153,706,087
Ensembl chr 5:153,682,789...153,706,087

G

ELL associated factor 2

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EAF2 mRNA

NCBI chr11:77,465,585...77,509,993
Ensembl chr11:77,406,020...77,509,993

G

enoyl CoA hydratase domain containing 2

decreases expression

ISO

belinostat results in decreased expression of ECHDC2 mRNA

NCBI chr 5:122,915,874...122,934,860
Ensembl chr 5:128,144,425...128,163,610

G

endothelin 1

increases expression
multiple interactions

ISO

belinostat results in increased expression of EDN1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDN1 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:22,660,799...22,666,687
Ensembl chr17:22,660,799...22,666,687

G

endothelin receptor type A

increases expression
multiple interactions

ISO

belinostat results in increased expression of EDNRA mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRA mRNA

PMID:26272509 PMID:27188386

NCBI chr19:47,137,360...47,207,961
Ensembl chr19:47,137,771...47,201,284

G

endothelin receptor type B

multiple interactions
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA
belinostat results in increased expression of EDNRB mRNA

PMID:26272509 PMID:27188386

NCBI chr15:87,055,490...87,086,765
Ensembl chr15:87,057,691...87,086,765

G

eukaryotic translation elongation factor 1 alpha 1

affects expression

ISO

belinostat affects the expression of EEF1A1 mRNA

NCBI chr 8:88,221,839...88,225,688
Ensembl chr 8:88,221,843...88,225,072

G

EF-hand calcium binding domain 2

decreases expression

ISO

belinostat results in decreased expression of DRC8 mRNA

NCBI chr13:90,152,002...90,237,918
Ensembl chr13:92,684,086...92,782,558

G

ephrin A1

multiple interactions
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFNA1 mRNA
belinostat results in increased expression of EFNA1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:176,979,434...176,988,675
Ensembl chr 2:176,979,434...176,988,726

G

epidermal growth factor

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGF mRNA

NCBI chr 2:220,893,660...220,976,331
Ensembl chr 2:220,893,660...220,976,297

G

eukaryotic translation initiation factor 4, gamma 2

decreases expression

ISO

belinostat results in decreased expression of EIF4G2 mRNA

NCBI chr 1:165,181,433...165,193,583
Ensembl chr 1:174,616,103...174,628,252

G

ELMO domain containing 1

increases expression
multiple interactions

ISO

belinostat results in increased expression of ELMOD1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELMOD1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:54,298,363...54,355,348
Ensembl chr 8:63,137,295...63,251,322

G

ELOVL fatty acid elongase 2

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of ELOVL2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELOVL2 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:23,544,598...23,584,855
Ensembl chr17:23,750,350...23,790,601

G

erythrocyte membrane protein band 4.1-like 3

increases expression
multiple interactions

ISO

belinostat results in increased expression of EPB41L3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:109,056,178...109,260,607
Ensembl chr 9:116,462,807...116,707,274

G

erythrocyte membrane protein band 4.1 like 5

increases expression

ISO

belinostat results in increased expression of EPB41L5 mRNA

NCBI chr13:30,670,792...30,770,213
Ensembl chr13:33,223,589...33,321,133

G

epithelial cell adhesion molecule

increases expression

ISO

belinostat results in increased expression of EPCAM mRNA

NCBI chr 6:12,633,715...12,649,678
Ensembl chr 6:12,631,611...12,649,702

G

ependymin related 1

decreases expression

ISO

belinostat results in decreased expression of EPDR1 mRNA

NCBI chr17:45,333,932...45,358,597
Ensembl chr17:50,029,256...50,054,250

G

Eph receptor A1

increases expression
multiple interactions

ISO

belinostat results in increased expression of EPHA1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:72,213,022...72,227,543
Ensembl chr 4:72,213,037...72,227,474

G

Eph receptor A3

increases expression

ISO

belinostat results in increased expression of EPHA3 mRNA

NCBI chr11:14,585,041...14,920,721
Ensembl chr11:14,586,727...14,920,425

G

Eph receptor A7

increases expression

ISO

belinostat results in increased expression of EPHA7 mRNA

NCBI chr 5:42,975,353...43,128,703
Ensembl chr 5:47,771,865...47,925,058

G

Eph receptor B2

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of EPHB2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:154,179,065...154,360,459
Ensembl chr 5:154,179,065...154,360,615

G

erythroblast membrane associated protein (Scianna blood group)

decreases expression

ISO

belinostat results in decreased expression of ERMAP mRNA

NCBI chr 5:132,788,847...132,803,030
Ensembl chr 5:138,065,824...138,087,015

G

ETS proto-oncogene 1, transcription factor

increases expression
multiple interactions

ISO

belinostat results in increased expression of ETS1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETS1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:39,303,936...39,426,022
Ensembl chr 8:39,303,925...39,426,021

G

ETS variant transcription factor 5

decreases expression

ISO

belinostat results in decreased expression of ETV5 mRNA

NCBI chr11:78,608,618...78,666,221
Ensembl chr11:92,113,224...92,170,767

G

exonuclease 1

decreases expression

ISO

belinostat results in decreased expression of EXO1 protein

NCBI chr13:87,809,725...87,834,654
Ensembl chr13:90,342,018...90,366,861

G

enhancer of zeste 1 polycomb repressive complex 2 subunit

increases expression

ISO

belinostat results in increased expression of EZH1 mRNA

NCBI chr10:86,626,307...86,662,257
Ensembl chr10:86,626,308...86,652,620

G

coagulation factor X

decreases expression

ISO

belinostat results in decreased expression of F10 mRNA

NCBI chr16:76,468,834...76,488,141
Ensembl chr16:83,170,977...83,190,280

G

coagulation factor XIII A1 chain

increases expression

ISO

belinostat results in increased expression of F13A1 mRNA

NCBI chr17:28,021,197...28,197,960
Ensembl chr17:28,020,845...28,197,948

G

F2R like trypsin receptor 1

decreases expression
multiple interactions
increases expression

ISO

belinostat results in decreased expression of F2RL1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL1 mRNA
belinostat results in increased expression of F2RL1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:28,507,003...28,519,954
Ensembl chr 2:28,507,003...28,519,954

G

fatty acid binding protein 1

decreases expression

ISO

belinostat results in decreased expression of FABP1 mRNA

NCBI chr 4:104,744,302...104,753,119
Ensembl chr 4:104,744,309...104,753,113

G

fatty acid binding protein 3

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FABP3 mRNA

NCBI chr 5:142,651,962...142,658,707
Ensembl chr 5:147,936,119...147,942,881

G

family with sequence similarity 174, member B

decreases expression

ISO

belinostat results in decreased expression of FAM174B mRNA

NCBI chr 1:127,515,393...127,618,591
Ensembl chr 1:136,925,151...137,035,589

G

family with sequence similarity 222, member A

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of FAM222A mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM222A mRNA

PMID:26272509 PMID:27188386

NCBI chr12:41,982,064...42,033,085
Ensembl chr12:47,647,405...47,693,703

G

family with sequence similarity 43, member A

increases expression
multiple interactions

ISO

belinostat results in increased expression of FAM43A mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM43A mRNA

PMID:26272509 PMID:27188386

NCBI chr11:70,128,253...70,131,401
Ensembl chr11:83,633,154...83,695,297

G

FA complementation group G

decreases expression

ISO

belinostat results in decreased expression of FANCG mRNA

NCBI chr 5:57,230,287...57,240,067
Ensembl chr 5:62,027,500...62,035,787

G

fatty acyl CoA reductase 2

decreases expression

ISO

belinostat results in decreased expression of FAR2 mRNA

NCBI chr 4:180,973,968...181,087,862
Ensembl chr 4:182,705,381...182,825,279

G

fibulin 1

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of FBLN1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:118,190,347...118,269,965
Ensembl chr 7:118,190,478...118,269,965

G

fibulin 2

decreases expression

ISO

belinostat results in decreased expression of FBLN2 mRNA

NCBI chr 4:123,704,289...123,763,857
Ensembl chr 4:125,261,607...125,321,029

G

fibulin 7

multiple interactions
decreases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN7 mRNA
belinostat results in decreased expression of FBLN7 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:116,111,581...116,145,839
Ensembl chr 3:136,564,917...136,601,198

G

fibrillin 1

decreases expression

ISO

belinostat results in decreased expression of FBN1 mRNA

NCBI chr 3:112,554,257...112,750,835
Ensembl chr 3:133,008,361...133,204,283

G

F-box protein 43

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of FBXO43 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO43 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:69,218,298...69,231,873
Ensembl chr 7:69,218,299...69,230,310

G

F-box and WD repeat domain containing 4

decreases expression

ISO

belinostat results in decreased expression of FBXW4 mRNA

NCBI chr 1:244,426,892...244,514,188
Ensembl chr 1:254,375,923...254,463,277

G

fibroblast growth factor 4

increases expression
multiple interactions

ISO

belinostat results in increased expression of FGF4 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:209,453,229...209,457,085
Ensembl chr 1:209,453,229...209,457,085

G

fibroblast growth factor 9

multiple interactions
decreases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA
belinostat results in decreased expression of FGF9 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:32,208,993...32,254,952
Ensembl chr15:36,325,599...36,367,926

G

Fms related receptor tyrosine kinase 1

increases expression
multiple interactions

ISO

belinostat results in increased expression of FLT1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLT1 mRNA

PMID:26272509 PMID:27188386

NCBI chr12:7,296,899...7,468,626
Ensembl chr12:12,333,430...12,504,750

G

flavin containing dimethylaniline monoxygenase 5

decreases expression

ISO

belinostat results in decreased expression of FMO5 mRNA

NCBI chr 2:185,197,184...185,249,699
Ensembl chr 2:187,910,964...187,938,464

G

folate receptor alpha

decreases expression

ISO

belinostat results in decreased expression of FOLR1 mRNA

NCBI chr 1:165,631,462...165,650,430
Ensembl chr 1:165,631,462...165,642,669

G

forkhead box C2

increases expression

ISO

belinostat results in increased expression of FOXC2 mRNA

NCBI chr19:66,094,718...66,097,420
Ensembl chr19:66,094,700...66,153,977

G

forkhead box D3

increases expression
multiple interactions

ISO

belinostat results in increased expression of FOXD3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXD3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:114,335,084...114,337,450
Ensembl chr 5:119,450,394...119,452,786

G

forkhead box H1

increases expression
multiple interactions

ISO

belinostat results in increased expression of FOXH1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXH1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:108,387,969...108,391,566
Ensembl chr 7:110,268,612...110,270,692

G

forkhead box O1

multiple interactions
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXO1 mRNA
belinostat results in increased expression of FOXO1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:138,462,974...138,541,420
Ensembl chr 2:138,462,697...138,541,419

G

Fras1 related extracellular matrix 1

decreases expression

ISO

belinostat results in decreased expression of FREM1 mRNA

NCBI chr 5:97,321,266...97,469,523
Ensembl chr 5:102,367,201...102,515,404

G

ferric-chelate reductase 1-like

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRRS1L mRNA

NCBI chr 5:71,655,911...71,690,132
Ensembl chr 5:76,451,101...76,485,316

G

fucosyltransferase 9

increases expression

ISO

belinostat results in increased expression of FUT9 mRNA

NCBI chr 5:39,351,815...39,565,256
Ensembl chr 5:44,146,152...44,362,823

G

frizzled class receptor 5

decreases expression

ISO

belinostat results in decreased expression of FZD5 mRNA

NCBI chr 9:73,606,860...73,614,039
Ensembl chr 9:73,606,860...73,618,612

G

frizzled class receptor 7

increases expression
multiple interactions

ISO

belinostat results in increased expression of FZD7 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD7 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:68,425,538...68,428,357
Ensembl chr 9:68,411,259...68,432,585

G

gamma-aminobutyric acid type A receptor subunit beta 3

increases expression
multiple interactions

ISO

belinostat results in increased expression of GABRB3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:108,467,047...108,702,522
Ensembl chr 1:117,431,842...117,836,725

G

glutamate decarboxylase 1

increases expression
multiple interactions

ISO

belinostat results in increased expression of GAD1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAD1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:55,369,704...55,410,335
Ensembl chr 3:75,777,534...75,818,759

G

growth arrest and DNA-damage-inducible, alpha

increases expression

ISO

belinostat results in increased expression of GADD45A mRNA; belinostat results in increased expression of GADD45A protein

NCBI chr 4:97,484,497...97,486,799
Ensembl chr 4:97,484,502...97,486,807

G

polypeptide N-acetylgalactosaminyltransferase 17

decreases expression

ISO

belinostat results in decreased expression of GALNT17 mRNA

NCBI chr12:25,323,230...25,781,897
Ensembl chr12:30,959,447...31,418,149

G

polypeptide N-acetylgalactosaminyltransferase 3

multiple interactions
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT3 mRNA
belinostat results in increased expression of GALNT3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:50,742,500...50,779,266
Ensembl chr 3:71,150,571...71,174,323

G

growth associated protein 43

increases expression
multiple interactions

ISO

belinostat results in increased expression of GAP43 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAP43 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:71,882,131...71,975,799
Ensembl chr11:71,882,131...71,975,797

G

GATA binding protein 3

increases expression
multiple interactions

ISO

belinostat results in increased expression of GATA3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA3 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:73,544,234...73,575,670
Ensembl chr17:73,553,548...73,575,670

G

glucosylceramidase beta 3

decreases expression

ISO

belinostat results in decreased expression of GBA3 mRNA

NCBI chr14:60,574,974...60,721,411
Ensembl chr14:64,787,601...64,934,043

G

1,4-alpha-glucan branching enzyme 1

decreases expression

ISO

belinostat results in decreased expression of GBE1 mRNA

NCBI chr11:8,734,806...9,000,226
Ensembl chr11:22,181,103...22,446,638

G

glycine C-acetyltransferase

decreases expression

ISO

belinostat results in decreased expression of GCAT mRNA

NCBI chr 7:110,595,126...110,601,474
Ensembl chr 7:112,475,496...112,482,664

G

ganglioside-induced differentiation-associated protein 1-like 1

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDAP1L1 mRNA

NCBI chr 3:152,110,225...152,129,693
Ensembl chr 3:172,509,564...172,549,125

G

GDNF family receptor alpha 1

multiple interactions
decreases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GFRA1 mRNA
belinostat results in decreased expression of GFRA1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:257,315,682...257,552,004
Ensembl chr 1:267,326,817...267,556,501

G

galactosidase, beta 1-like 3

increases expression
multiple interactions

ISO

belinostat results in increased expression of GLB1L3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLB1L3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:25,179,165...25,220,904
Ensembl chr 8:33,454,914...33,496,641

G

gliomedin

increases expression

ISO

belinostat results in increased expression of GLDN mRNA

NCBI chr 8:54,679,015...54,723,198
Ensembl chr 8:63,575,270...63,619,346

G

GLIS family zinc finger 3

decreases expression

ISO

belinostat results in decreased expression of GLIS3 mRNA

NCBI chr 1:235,389,567...235,809,416
Ensembl chr 1:235,392,651...235,809,221

G

glycosyltransferase 8 domain containing 2

decreases expression

ISO

belinostat results in decreased expression of GLT8D2 mRNA

NCBI chr 7:21,029,534...21,081,081
Ensembl chr 7:22,917,100...22,968,930

G

G protein subunit gamma 11

increases expression

ISO

belinostat results in increased expression of GNG11 mRNA

NCBI chr 4:32,023,003...32,028,443
Ensembl chr 4:32,977,664...32,984,438

G

glypican 6

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of GPC6 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC6 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:94,030,218...95,027,883
Ensembl chr15:100,437,943...101,435,027

G

G protein-coupled receptor 143

decreases expression

ISO

belinostat results in decreased expression of GPR143 mRNA

NCBI chr X:25,498,601...25,523,408
Ensembl chr X:25,498,601...25,523,400

G

G protein-coupled receptor 27

decreases expression

ISO

belinostat results in decreased expression of GPR27 mRNA

NCBI chr 4:133,884,894...133,886,027
Ensembl chr 4:133,883,234...133,904,093

G

glutathione peroxidase 7

decreases expression

ISO

belinostat results in decreased expression of GPX7 mRNA

NCBI chr 5:123,145,151...123,153,141
Ensembl chr 5:128,372,875...128,381,725

G

gremlin 1, DAN family BMP antagonist

increases expression
multiple interactions

ISO

belinostat results in increased expression of GREM1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GREM1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:100,512,317...100,524,001
Ensembl chr 3:120,966,623...120,979,089

G

grainyhead-like transcription factor 3

increases expression
multiple interactions

ISO

belinostat results in increased expression of GRHL3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:153,057,760...153,089,890
Ensembl chr 5:153,057,760...153,089,890

G

glutamate ionotropic receptor AMPA type subunit 3

increases expression

ISO

belinostat results in increased expression of GRIA3 mRNA

NCBI chr X:120,238,515...120,504,106
Ensembl chr X:125,103,782...125,369,679

G

glutamate ionotropic receptor kainate type subunit 1

increases expression

ISO

belinostat results in increased expression of GRIK1 mRNA

NCBI chr11:40,655,974...41,056,966
Ensembl chr11:40,655,975...41,056,517

G

G protein-coupled receptor kinase 6

decreases expression

ISO

belinostat results in decreased expression of GRK6 mRNA

NCBI chr17:9,177,018...9,192,813
Ensembl chr17:9,182,160...9,197,954

G

glycogen synthase kinase 3 beta

increases phosphorylation

ISO

belinostat results in increased phosphorylation of GSK3B protein

NCBI chr11:76,004,502...76,154,665
Ensembl chr11:76,009,507...76,153,249

G

H1.0 linker histone

increases expression

ISO

belinostat results in increased expression of H1-0 mRNA

PMID:19606018 PMID:27188386

NCBI chr 7:110,592,834...110,594,694
Ensembl chr 7:112,473,222...112,475,006

G

H1.10 linker histone

increases expression

ISO

belinostat results in increased expression of H1-10 mRNA

NCBI chr 4:120,440,515...120,441,578
Ensembl chr 4:121,997,831...121,998,966

G

H2B clustered histone 12

multiple interactions
decreases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC12 mRNA
belinostat results in decreased expression of H2BC12 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:42,485,699...42,486,162
Ensembl chr17:47,121,467...47,182,816

G

hyaluronan and proteoglycan link protein 1

multiple interactions
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAPLN1 mRNA
belinostat results in increased expression of HAPLN1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:20,631,640...20,696,388
Ensembl chr 2:22,366,967...22,429,098

G

hyaluronan and proteoglycan link protein 4

decreases expression

ISO

belinostat results in decreased expression of HAPLN4 mRNA

NCBI chr16:19,333,106...19,341,243
Ensembl chr16:19,367,041...19,375,442

G

hemoglobin subunit epsilon 1

decreases expression

ISO

belinostat results in decreased expression of HBE1 mRNA

NCBI chr 1:158,282,931...158,458,855
Ensembl chr 1:167,694,825...167,696,280

G

heart development protein with EGF-like domains 1

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of HEG1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HEG1 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:67,006,954...67,095,020
Ensembl chr11:80,512,096...80,600,092

G

hes family bHLH transcription factor 5

multiple interactions
decreases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES5 mRNA
belinostat results in decreased expression of HES5 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:170,804,511...170,807,988
Ensembl chr 5:170,803,940...170,806,021

G

HESX homeobox 1

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of HESX1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HESX1 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:2,198,589...2,200,694
Ensembl chr16:2,198,589...2,200,694

G

hes-related family bHLH transcription factor with YRPW motif 2

multiple interactions
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HEY2 mRNA
belinostat results in increased expression of HEY2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:26,822,131...26,832,218
Ensembl chr 1:28,641,057...28,651,187

G

homogentisate 1, 2-dioxygenase

decreases expression

ISO

belinostat results in decreased expression of HGD mRNA

NCBI chr11:76,592,202...76,643,776
Ensembl chr11:76,592,204...76,643,767

G

hematopoietically expressed homeobox

increases expression
multiple interactions

ISO

belinostat results in increased expression of HHEX mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HHEX mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:244,602,945...244,608,532
Ensembl chr 1:244,602,825...244,608,604

G

histone cluster 1 H2A family like 1

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2AC6 mRNA

NCBI chr17:42,707,954...42,708,420

G

histone cluster 1 H2B family member D

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of H2BC5 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC5 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:42,792,887...42,793,268

G

hexokinase domain containing 1

decreases expression

ISO

belinostat results in decreased expression of HKDC1 mRNA

NCBI chr20:30,335,322...30,373,792
Ensembl chr20:30,878,319...30,916,704

G

H6 family homeobox 2

increases expression
multiple interactions

ISO

belinostat results in increased expression of HMX2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMX2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:186,319,110...186,326,771
Ensembl chr 1:195,749,284...195,756,945

G

homer scaffold protein 2

decreases expression

ISO

belinostat results in decreased expression of HOMER2 mRNA

NCBI chr 1:135,558,977...135,659,780
Ensembl chr 1:144,976,436...145,068,997

G

homeo box D3

increases expression

ISO

belinostat results in increased expression of HOXD3 mRNA

NCBI chr 3:80,041,598...80,057,700
Ensembl chr 3:80,046,126...80,057,700

G

homeo box D4

increases expression

ISO

belinostat results in increased expression of HOXD4 mRNA

NCBI chr 3:80,021,886...80,041,462
Ensembl chr 3:80,036,900...80,038,948

G

4-hydroxyphenylpyruvate dioxygenase-like

increases expression
multiple interactions

ISO

belinostat results in increased expression of HPDL mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPDL mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:130,286,627...130,288,233
Ensembl chr 5:135,523,262...135,535,704

G

15-hydroxyprostaglandin dehydrogenase

increases expression

ISO

belinostat results in increased expression of HPGD mRNA

NCBI chr16:38,996,876...39,034,831
Ensembl chr16:38,996,876...39,034,831

G

hemopexin

decreases expression

ISO

belinostat results in decreased expression of HPX mRNA

NCBI chr 1:169,344,647...169,352,155
Ensembl chr 1:169,344,583...169,352,156

G

hormonally upregulated Neu-associated kinase

decreases expression

ISO

belinostat results in decreased expression of HUNK mRNA

NCBI chr11:29,641,122...29,758,392
Ensembl chr11:43,127,244...43,244,502

G

HUS1 checkpoint clamp component

increases expression

ISO

belinostat results in increased expression of HUS1 mRNA

NCBI chr14:87,902,458...87,917,221
Ensembl chr14:87,902,458...87,917,134

G

hydroxypyruvate isomerase

decreases expression

ISO

belinostat results in decreased expression of HYI mRNA

NCBI chr 5:131,894,575...131,897,709
Ensembl chr 5:137,179,976...137,182,654

G

interactor of little elongation complex ELL subunit 2

increases expression

ISO

belinostat results in increased expression of ICE2 mRNA

NCBI chr 8:70,043,419...70,085,217
Ensembl chr 8:78,924,421...78,966,200

G

inhibitor of DNA binding 4

increases expression
multiple interactions

ISO

belinostat results in increased expression of ID4 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ID4 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:16,595,724...16,598,293
Ensembl chr17:16,595,724...16,598,492

G

isocitrate dehydrogenase (NAD(+)) 3 catalytic subunit alpha

increases expression
multiple interactions

ISO

belinostat results in increased expression of IDH3A mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDH3A mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:54,971,694...54,991,085
Ensembl chr 8:63,867,820...63,887,223

G

Idnk, gluconokinase

decreases expression

ISO

belinostat results in decreased expression of IDNK mRNA

NCBI chr17:6,483,575...6,490,780
Ensembl chr17:6,488,982...6,499,822

G

indoleamine 2,3-dioxygenase 1

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDO1 mRNA

NCBI chr16:74,133,259...74,145,328
Ensembl chr16:74,133,259...74,145,328

G

interferon-induced protein with tetratricopeptide repeats 3

decreases expression

ISO

belinostat results in decreased expression of IFIT3 mRNA

NCBI chr 1:232,114,166...232,119,311
Ensembl chr 1:241,526,880...241,532,521

G

interferon induced transmembrane protein 1

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFITM1 mRNA

NCBI chr 1:196,067,163...196,069,169
Ensembl chr 1:205,496,807...205,498,776

G

interferon gamma

multiple interactions

ISO

belinostat inhibits the reaction [IL15 protein results in increased expression of IFNG protein]

NCBI chr 7:55,789,180...55,793,216
Ensembl chr 7:55,761,736...55,793,216

G

interferon gamma receptor 1

increases expression

ISO

belinostat results in increased expression of IFNGR1 mRNA

NCBI chr 1:16,152,811...16,171,439
Ensembl chr 1:16,152,879...16,171,437

G

insulin-like growth factor 1

increases expression

ISO

belinostat results in increased expression of IGF1 mRNA

NCBI chr 7:24,169,608...24,249,446
Ensembl chr 7:24,130,137...24,246,764

G

interleukin 15

multiple interactions

ISO

belinostat inhibits the reaction [IL15 protein results in increased expression of IFNG protein]

NCBI chr19:25,640,025...25,706,818
Ensembl chr19:42,545,346...42,611,348

G

interleukin 17D

decreases expression

ISO

belinostat results in decreased expression of IL17D mRNA

NCBI chr15:31,671,337...31,688,833
Ensembl chr15:35,786,898...35,804,391

G

interleukin 17 receptor B

decreases expression

ISO

belinostat results in decreased expression of IL17RB mRNA

NCBI chr16:5,180,431...5,194,125
Ensembl chr16:5,186,961...5,200,694

G

interleukin 17 receptor D

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of IL17RD mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL17RD mRNA

PMID:26272509 PMID:27188386

NCBI chr16:2,228,438...2,295,122
Ensembl chr16:2,235,169...2,301,850

G

interleukin 20 receptor subunit beta

increases expression
multiple interactions

ISO

belinostat results in increased expression of IL20RB mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL20RB mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:100,979,085...101,010,829
Ensembl chr 8:109,854,012...109,889,363

G

interleukin 4 receptor

decreases expression

ISO

belinostat results in decreased expression of IL4R mRNA

NCBI chr 1:189,545,739...189,570,639
Ensembl chr 1:189,544,988...189,570,636

G

interleukin 6

increases expression

ISO

belinostat results in increased expression of IL6 mRNA

NCBI chr 4:5,889,999...5,894,575
Ensembl chr 4:5,889,999...5,894,610

G

interphotoreceptor matrix proteoglycan 1

increases expression

ISO

belinostat results in increased expression of IMPG1 mRNA

NCBI chr 8:81,243,624...81,389,722
Ensembl chr 8:90,123,821...90,269,903

G

inner centromere protein

decreases expression

ISO

belinostat results in decreased expression of INCENP mRNA

NCBI chr 1:215,945,558...216,017,247
Ensembl chr 1:215,948,283...215,977,084

G

inhibin subunit beta A

increases expression
multiple interactions

ISO

belinostat results in increased expression of INHBA mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBA mRNA

PMID:26272509 PMID:27188386

NCBI chr17:53,787,159...53,810,942
Ensembl chr17:53,791,444...53,804,508

G

inositol polyphosphate-1-phosphatase

decreases expression

ISO

belinostat results in decreased expression of INPP1 mRNA

NCBI chr 9:48,688,037...48,717,793
Ensembl chr 9:56,161,852...56,234,569

G

iroquois homeobox 1

increases expression
multiple interactions

ISO

belinostat results in increased expression of IRX1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:31,294,615...31,300,444
Ensembl chr 1:33,123,122...33,128,951

G

iroquois homeobox 2

increases expression
multiple interactions

ISO

belinostat results in increased expression of IRX2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:30,660,960...30,666,378
Ensembl chr 1:32,489,512...32,494,930

G

integrin subunit alpha 2

increases expression

ISO

belinostat results in increased expression of ITGA2 mRNA

NCBI chr 2:46,520,345...46,621,487
Ensembl chr 2:48,253,412...48,354,509

G

integrin subunit alpha 3

decreases expression

ISO

belinostat results in decreased expression of ITGA3 mRNA

NCBI chr10:80,486,998...80,522,548
Ensembl chr10:80,486,999...80,518,901

G

integrin subunit beta 5

decreases expression

ISO

belinostat results in decreased expression of ITGB5 mRNA

NCBI chr11:66,828,428...66,944,231
Ensembl chr11:80,333,590...80,449,373

G

inter-alpha-trypsin inhibitor heavy chain 5

increases expression
multiple interactions

ISO

belinostat results in increased expression of ITIH5 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITIH5 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:68,248,115...68,352,216
Ensembl chr17:73,161,611...73,262,496

G

integral membrane protein 2A

increases expression

ISO

belinostat results in increased expression of ITM2A mRNA

NCBI chr X:72,486,383...72,492,344
Ensembl chr X:76,559,181...76,565,437

G

ITPRIP like 2

decreases expression

ISO

belinostat results in decreased expression of ITPRIPL2 mRNA

NCBI chr 1:172,801,152...172,803,047
Ensembl chr 1:182,231,093...182,245,858

G

JAZF zinc finger 1

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JAZF1 mRNA

NCBI chr 4:81,879,501...82,183,237
Ensembl chr 4:83,210,058...83,513,644

G

KAT8 regulatory NSL complex subunit 1-like

decreases expression

ISO

belinostat results in decreased expression of KANSL1L mRNA

NCBI chr 9:68,211,151...68,316,992
Ensembl chr 9:75,661,233...75,766,745

G

potassium inwardly-rectifying channel, subfamily J, member 13

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of KCNJ13 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ13 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:88,063,003...88,071,112
Ensembl chr 9:95,510,877...95,520,817

G

potassium inwardly-rectifying channel, subfamily J, member 2

decreases expression

ISO

belinostat results in decreased expression of KCNJ2 mRNA

NCBI chr10:96,060,834...96,071,397
Ensembl chr10:96,565,600...96,570,901

G

potassium inwardly-rectifying channel, subfamily J, member 3

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ3 mRNA

NCBI chr 3:39,944,896...40,106,646
Ensembl chr 3:60,354,146...60,518,104

G

lysine demethylase 4C

increases expression

ISO

belinostat results in increased expression of KDM4C mRNA

NCBI chr 5:88,100,710...88,306,821
Ensembl chr 5:93,146,969...93,353,040

G

kinase insert domain receptor

increases expression
multiple interactions

ISO

belinostat results in increased expression of KDR mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KDR mRNA

PMID:26272509 PMID:27188386

NCBI chr14:32,572,031...32,615,204
Ensembl chr14:32,572,049...32,615,192

G

Kelch-like ECH-associated protein 1

decreases expression

ISO

belinostat results in decreased expression of KEAP1 mRNA

NCBI chr 8:28,044,555...28,054,042
Ensembl chr 8:28,044,555...28,054,042

G

KIAA0040 ortholog

increases expression
multiple interactions

ISO

belinostat results in increased expression of KIAA0040 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA0040 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:72,274,519...72,312,103
Ensembl chr13:74,807,982...74,845,530

G

KLF transcription factor 5

increases expression
multiple interactions

ISO

belinostat results in increased expression of KLF5 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF5 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:76,060,320...76,079,445
Ensembl chr15:82,472,065...82,487,262

G

KLF transcription factor 9

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF9 mRNA

NCBI chr 1:230,126,646...230,151,641
Ensembl chr 1:230,126,646...230,151,641

G

kelch-like family member 18

increases expression

ISO

belinostat results in increased expression of KLHL18 mRNA

NCBI chr 8:110,400,679...110,459,442
Ensembl chr 8:119,279,081...119,337,719

G

karyopherin subunit beta 1

decreases expression

ISO

belinostat results in decreased expression of KPNB1 mRNA

NCBI chr10:82,642,082...82,670,856
Ensembl chr10:82,642,082...82,670,856

G

keratin 18

increases expression
multiple interactions

ISO

belinostat results in increased expression of KRT18 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT18 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:135,036,168...135,039,844
Ensembl chr 7:135,035,982...135,039,848
Ensembl chr10:135,035,982...135,039,848

G

lactamase, beta

multiple interactions
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACTB mRNA
belinostat results in increased expression of LACTB mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:67,571,504...67,587,592
Ensembl chr 8:76,452,349...76,468,716

G

laminin subunit alpha 4

increases expression
multiple interactions

ISO

belinostat results in increased expression of LAMA4 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMA4 mRNA

PMID:26272509 PMID:27188386

NCBI chr20:42,392,268...42,533,347
Ensembl chr20:43,946,898...44,087,972

G

lactase-like

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of LCTL mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LCTL mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:64,618,356...64,654,851
Ensembl chr 8:73,513,634...73,534,668

G

leucine-rich, glioma inactivated 1

increases expression

ISO

belinostat results in increased expression of LGI1 mRNA

NCBI chr 1:236,043,269...236,084,617
Ensembl chr 1:245,455,599...245,499,095

G

LIM homeobox 2

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of LHX2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LHX2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:42,523,345...42,553,646
Ensembl chr 3:42,535,744...42,553,645

G

LIM homeobox 8

increases expression
multiple interactions

ISO

belinostat results in increased expression of LHX8 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHX8 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:245,904,712...245,929,376
Ensembl chr 2:245,904,712...245,929,376

G

LIF receptor subunit alpha

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIFR mRNA

NCBI chr 2:56,224,393...56,292,988
Ensembl chr 2:57,952,975...58,020,364

G

LIM and calponin homology domains 1

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of LIMCH1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIMCH1 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:41,466,433...41,779,477
Ensembl chr14:41,466,433...41,778,837

G

lipase G, endothelial type

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIPG mRNA

NCBI chr18:68,514,923...68,536,105
Ensembl chr18:70,790,077...70,812,260

G

lectin, mannose-binding, 1

decreases expression

ISO

belinostat results in decreased expression of LMAN1 mRNA

NCBI chr18:59,508,996...59,530,873
Ensembl chr18:61,772,917...61,800,820

G

LIM domain only 2

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of LMO2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:90,355,234...90,377,970
Ensembl chr 3:110,809,912...110,833,075

G

LIM domain only 3

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of LMO3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:171,234,686...171,297,677
Ensembl chr 4:172,965,951...173,025,156

G

lysophosphatidic acid receptor 1

decreases expression

ISO

belinostat results in decreased expression of LPAR1 mRNA

NCBI chr 5:78,024,139...78,147,071
Ensembl chr 5:78,024,139...78,142,188

G

lysophosphatidic acid receptor 6

increases expression

ISO

belinostat results in increased expression of LPAR6 mRNA

NCBI chr15:48,416,548...48,418,357
Ensembl chr15:54,823,717...54,978,783

G

leucine rich repeat containing 10B

decreases expression

ISO

belinostat results in decreased expression of LRRC10B mRNA

NCBI chr 1:216,521,402...216,522,630
Ensembl chr 1:216,520,677...216,524,310

G

leucine rich repeat containing 17

increases expression

ISO

belinostat results in increased expression of LRRC17 mRNA

NCBI chr 4:13,501,428...13,531,845
Ensembl chr 4:14,393,640...14,424,048

G

leucine rich repeat containing 55

multiple interactions
decreases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC55 mRNA
belinostat results in decreased expression of LRRC55 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:70,269,908...70,280,651
Ensembl chr 3:90,680,160...90,685,280

G

leucine rich repeat neuronal 3

increases expression
multiple interactions

ISO

belinostat results in increased expression of LRRN3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:58,489,060...58,520,322
Ensembl chr 6:64,215,878...64,247,614

G

leucine rich repeat transmembrane neuronal 1

increases expression
multiple interactions

ISO

belinostat results in increased expression of LRRTM1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRTM1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:111,246,213...111,295,638
Ensembl chr 4:111,235,054...111,276,818

G

lysozyme-like 6

multiple interactions
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYZL6 mRNA
belinostat results in increased expression of LYZL6 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:88,544,342...88,549,177
Ensembl chr10:89,044,375...89,049,210

G

MET transcriptional regulator MACC1

increases expression
multiple interactions

ISO

belinostat results in increased expression of MACC1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MACC1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:140,352,690...140,430,255
Ensembl chr 6:146,495,861...146,574,260

G

macroH2A.1 histone

multiple interactions
decreases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROH2A1 mRNA
belinostat results in decreased expression of MACROH2A1 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:8,484,340...8,547,268
Ensembl chr17:8,484,246...8,547,257

G

membrane associated guanylate kinase, WW and PDZ domain containing 2

increases expression
multiple interactions

ISO

belinostat results in increased expression of MAGI2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAGI2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:14,386,389...15,870,036
Ensembl chr 4:15,278,518...16,762,199

G

microtubule-associated protein 1 light chain 3 beta

increases expression

ISO

belinostat results in increased expression of MAP1LC3B mRNA

NCBI chr19:66,571,631...66,582,270
Ensembl chr19:66,574,407...66,584,358
Ensembl chr16:66,574,407...66,584,358

G

mitogen-activated protein kinase kinase kinase 5

decreases expression

ISO

belinostat results in decreased expression of MAP3K5 mRNA

NCBI chr 1:14,685,776...14,904,935
Ensembl chr 1:16,505,596...16,723,898

G

mitogen-activated protein kinase kinase kinase 8

increases expression

ISO

belinostat results in increased expression of MAP3K8 mRNA

NCBI chr17:53,382,908...53,403,216
Ensembl chr17:58,078,320...58,098,452

G

microtubule-associated protein 6

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of MAP6 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP6 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:162,980,339...163,046,548
Ensembl chr 1:162,980,181...163,046,548

G

MAP7 domain containing 2

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of MAP7D2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP7D2 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:35,372,453...35,488,073
Ensembl chr X:39,181,091...39,296,695

G

MARVEL domain containing 1

decreases expression

ISO

belinostat results in decreased expression of MARVELD1 mRNA

NCBI chr 1:240,954,050...240,958,101
Ensembl chr 1:250,903,342...250,907,393

G

muscleblind-like splicing regulator 3

increases expression
multiple interactions

ISO

belinostat results in increased expression of MBNL3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBNL3 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:130,641,942...130,737,179
Ensembl chr X:135,532,494...135,621,976

G

melanin-concentrating hormone receptor 1

decreases expression

ISO

belinostat results in decreased expression of MCHR1 mRNA

NCBI chr 7:112,761,554...112,764,746
Ensembl chr 7:114,641,580...114,644,919

G

minichromosome maintenance complex component 3

decreases expression

ISO

belinostat results in decreased expression of MCM3 mRNA

NCBI chr 9:23,219,169...23,237,314
Ensembl chr 9:30,715,602...30,733,746

G

minichromosome maintenance complex component 7

decreases expression

ISO

belinostat results in decreased expression of MCM7 mRNA

NCBI chr12:17,042,207...17,049,470
Ensembl chr12:22,155,921...22,163,771

G

mucolipin TRP cation channel 3

increases expression
multiple interactions

ISO

belinostat results in increased expression of MCOLN3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCOLN3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:235,008,716...235,042,885
Ensembl chr 2:237,626,302...237,705,769

G

mesenchyme homeobox 1

increases expression
multiple interactions

ISO

belinostat results in increased expression of MEOX1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEOX1 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:86,818,450...86,837,563
Ensembl chr10:87,318,695...87,337,976

G

MFNG O-fucosylpeptide 3-beta-N-acetylglucosaminyltransferase

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of MFNG mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:110,310,810...110,328,653
Ensembl chr 7:112,161,071...112,209,129

G

maltase-glucoamylase

decreases expression

ISO

belinostat results in decreased expression of MGAM mRNA

NCBI chr 4:69,441,626...69,602,068
Ensembl chr 4:70,408,263...70,568,752

G

myocardial infarction associated transcript

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of MIAT mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIAT mRNA

PMID:26272509 PMID:27188386

NCBI chr12:44,414,620...44,429,852

G

melan-A

decreases expression

ISO

belinostat results in decreased expression of MLANA mRNA

NCBI chr 1:227,469,537...227,483,343
Ensembl chr 1:236,883,075...236,896,880

G

mutL homolog 1

multiple interactions

ISO

belinostat promotes the reaction [decitabine results in increased expression of MLH1 protein]

NCBI chr 8:120,074,871...120,112,109
Ensembl chr 8:120,065,900...120,112,011

G

N-methylpurine-DNA glycosylase

increases expression

ISO

belinostat results in increased expression of MPG mRNA

NCBI chr10:15,396,246...15,402,528
Ensembl chr10:15,899,635...15,907,052

G

metallophosphoesterase domain containing 2

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of MPPED2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MPPED2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:93,180,895...93,355,605
Ensembl chr 3:113,635,407...113,811,783

G

msh homeobox 1

increases expression
multiple interactions

ISO

belinostat results in increased expression of MSX1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:77,185,802...77,189,735
Ensembl chr14:77,185,802...77,189,735

G

msh homeobox 2

multiple interactions
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX2 mRNA
belinostat results in increased expression of MSX2 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:11,102,284...11,107,949
Ensembl chr17:11,102,247...11,107,945

G

methenyltetrahydrofolate synthetase

decreases expression

ISO

belinostat results in decreased expression of MTHFS mRNA

NCBI chr 8:89,729,498...89,801,998
Ensembl chr 8:98,609,399...98,752,036

G

mucin 15, cell surface associated

multiple interactions
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC15 mRNA
belinostat results in increased expression of MUC15 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:97,294,728...97,308,641
Ensembl chr 3:117,749,324...117,762,101

G

myosin regulatory light chain interacting protein

increases expression
multiple interactions

ISO

belinostat results in increased expression of MYLIP mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA

PMID:26272509 PMID:27188386

NCBI chr17:19,492,826...19,514,490
Ensembl chr17:19,492,826...19,514,471

G

myosin light chain kinase

decreases expression

ISO

belinostat results in decreased expression of MYLK mRNA

NCBI chr11:65,783,008...66,030,239
Ensembl chr11:79,288,243...79,535,659

G

myosin IIIB

increases expression

ISO

belinostat results in increased expression of MYO3B mRNA

NCBI chr 3:75,228,017...75,636,272
Ensembl chr 3:75,228,017...75,636,272

G

myoferlin

increases expression

ISO

belinostat results in increased expression of MYOF mRNA

NCBI chr 1:235,673,666...235,822,413
Ensembl chr 1:245,086,109...245,234,768

G

Nanog homeobox

increases expression
multiple interactions

ISO

belinostat results in increased expression of NANOG mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANOG mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:155,943,737...155,951,116
Ensembl chr 4:157,615,687...157,623,061

G

nanos C2HC-type zinc finger 1

decreases expression

ISO

belinostat results in decreased expression of NANOS1 mRNA

NCBI chr 1:259,897,663...259,901,561
Ensembl chr 1:269,883,536...269,895,417

G

neuron navigator 3

increases expression

ISO

belinostat results in increased expression of NAV3 mRNA

NCBI chr 7:46,938,577...47,726,839
Ensembl chr 7:46,940,670...47,504,893

G

neurocalcin delta

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of NCALD mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCALD mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:68,532,671...68,964,740
Ensembl chr 7:70,419,433...70,849,482

G

neurocan

decreases expression

ISO

belinostat results in decreased expression of NCAN mRNA

NCBI chr16:19,301,969...19,328,436
Ensembl chr16:19,335,907...19,362,371

G

norrin cystine knot growth factor NDP

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of NDP mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDP mRNA

PMID:26272509 PMID:27188386

NCBI chr X:8,379,569...8,404,019
Ensembl chr X:8,379,569...8,406,802

G

neurofilament light chain

increases expression

ISO

belinostat results in increased expression of NEFL mRNA

NCBI chr15:46,477,330...46,481,203
Ensembl chr15:46,458,204...46,482,515

G

neuronal growth regulator 1

increases expression

ISO

belinostat results in increased expression of NEGR1 mRNA

NCBI chr 2:245,624,460...246,359,605
Ensembl chr 2:248,283,353...249,018,410

G

neural EGFL like 2

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of NELL2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NELL2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:126,343,089...126,662,903
Ensembl chr 7:128,078,103...128,651,917

G

neuropilin and tolloid like 2

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of NETO2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NETO2 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:37,517,518...37,588,961
Ensembl chr19:37,517,587...37,591,413

G

neurite extension and migration factor

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEXMIF mRNA

NCBI chr X:69,088,076...69,219,253
Ensembl chr X:73,153,786...73,178,639

G

nuclear factor kappa B subunit 1

multiple interactions
increases expression

ISO

Bortezomib inhibits the reaction [belinostat results in increased expression of NFKB1 protein]

NCBI chr 2:224,016,214...224,132,135
Ensembl chr 2:226,689,745...226,783,088

G

NFKB inhibitor alpha

increases expression
multiple interactions

ISO

belinostat results in increased expression of NFKBIA protein
Bortezomib inhibits the reaction [belinostat results in increased expression of NFKBIA protein]

NCBI chr 6:78,593,844...78,597,307
Ensembl chr 6:78,593,847...78,597,072

G

neuronal guanine nucleotide exchange factor

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NGEF mRNA

NCBI chr 9:95,594,823...95,692,381
Ensembl chr 9:95,594,823...95,692,251

G

NIPA-like domain containing 2

decreases expression

ISO

belinostat results in decreased expression of NIPAL2 mRNA

NCBI chr 7:65,774,477...65,884,807
Ensembl chr 7:67,659,628...67,769,959

G

neuroligin 3

multiple interactions
decreases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN3 mRNA
belinostat results in decreased expression of NLGN3 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:70,469,251...70,497,380
Ensembl chr X:70,469,457...70,497,379

G

NME/NM23 family member 8

multiple interactions
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NME8 mRNA
belinostat results in increased expression of NME8 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:45,237,022...45,304,948
Ensembl chr17:49,932,860...50,000,608

G

N-myc (and STAT) interactor

increases expression
multiple interactions

ISO

belinostat results in increased expression of NMI mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMI mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:36,415,607...36,439,716
Ensembl chr 3:56,811,314...56,848,717

G

nocturnin

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOCT mRNA

NCBI chr 2:135,271,189...135,291,407
Ensembl chr 2:137,422,074...137,442,282

G

noggin

increases expression
multiple interactions

ISO

belinostat results in increased expression of NOG mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADA mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADAM12 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRG1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ADGRL3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ANKS1B mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARHGEF37 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ARNT2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of B3GNT5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of BCL2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C14ORF39 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CALML4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCKBR mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CCND2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNKSR2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CNTN3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of COLGALT2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of CRYBA4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DAZL mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DENND1A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of DGKI mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EGF mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ELOVL2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EOLA2-DT mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of EPHB2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FAM222A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBLN7 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FBXO43 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FGF9 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of FRRS1L mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GFRA1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GPC6 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of GSEC mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2AC6 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC12 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of H2BC5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HEG1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HES5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HESX1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HLA-DMB mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of IL17RD mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ13 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KCNJ3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of KIAA1549L mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LCTL mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LHX2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIMCH1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LIPG mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LMO3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of LRRC55 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MACROH2A1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP6 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MAP7D2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MFNG mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MIAT mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of MPPED2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NCALD mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NDP mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NELL2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NETO2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NEXMIF mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NIFK-AS1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NLGN3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NOL4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRXN2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NUCB2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OPLAH mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PIEZO1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLD5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLXNC1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PNMA2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRSS23 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB33A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB3IP mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAX mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBFOX3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ROBO2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RPH3AL mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RSL1D1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RTN1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of S1PR3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SDSL mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHC3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHISAL1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC16A14 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC27A2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC9B2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMOC1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX6 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TNC mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TOX2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZEB1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ACSM3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADAMTS15 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ADCYAP1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANGPT1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANO3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ANXA2P2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARHGAP24 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ARRB1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ATP8B1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAG2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BAMBI mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BBS9 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BCL11A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BEX5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMP5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BMPER mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BNC2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BORCS8 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of BSPRY mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C11ORF96 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C19ORF33 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C8ORF34 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of C8ORF34-AS1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CASP8 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC140 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCDC69 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CCL26 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD24 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CD9 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CDH3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP126 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CEP85L mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHGA mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHODL mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRM3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CHRNA3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CIMAP3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CLDN7 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNMD mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CNTN1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COBL mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COL1A2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of COMTD1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CPNE4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CR1L mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRIP1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CRYBG1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CTHRC1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL12 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of CXCL5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DACT1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DCC mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPDC7 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DEPTOR mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DHRS2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DIAPH2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DNER mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPPA2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of DPPA5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EAF2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDN1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRA mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EDNRB mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EFNA1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ELMOD1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPB41L3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of EPHA1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ERVH48-1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ESRG mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ETS1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of F2RL1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FABP3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM162B mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FAM43A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FGF4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FLT1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXD3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXH1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FOXO1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of FZD7 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GABRB3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAD1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GALNT3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GAP43 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GATA3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GDAP1L1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GLB1L3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GREM1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of GRHL3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HAPLN1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HEY2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HHEX mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HLA-DPB2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HMX2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of HPDL mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ID4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDH3A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IDO1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFI16 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IFITM1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IL20RB mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of INHBA mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of IRX2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ITIH5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of JAZF1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KDR mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KIAA0040 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF5 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KLF9 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of KRT18 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LACTB mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LAMA4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LHX8 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LIFR mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC00491 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC00698 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LINC01003 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRN3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LRRTM1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of LYZL6 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MACC1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MAGI2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MBNL3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MCOLN3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MEOX1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MSX2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MUC15 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of MYLIP mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NANOG mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NEAT1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NGEF mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NME8 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NMI mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NOCT mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPFFR2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPY mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRP1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NWD2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFML3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX7 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH10 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH11Y mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFA mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDLIM1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDPN mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIPOX mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKDCC mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G2A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G4A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAAT3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAU mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PODXL mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POLR3G mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU2F3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU5F1B mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU5F1P3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU5F1P4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPARGC1B mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPIC mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1K mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R3B mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM14 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKACA mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRR15 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB3C mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RABGAP1L mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RARRES2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOB mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF144B mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF150 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF217 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RTP1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX1T1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A10 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SAT1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCG3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCGB3A2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCML1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCNN1A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA3E mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEPTIN6 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINB9 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINI1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEZ6 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFMBT2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGK3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC1A3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35D3 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC38A4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC38A6 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLCO1B1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLCO4C1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMARCA2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAP25 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX8 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SP140L mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STMN2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1C2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACSTD2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAFA2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TC2N mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2C mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFPI mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THRB mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM30B mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM64 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFSF11 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNIK mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNN mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TPD52L1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRNP1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TTC29 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT3A1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT8 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP28 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UTF1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VASH2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VENTX mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VEPH1 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WFDC2 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT4 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP42 mRNA; [NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZIC3 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:74,625,874...74,627,501
Ensembl chr10:74,625,875...74,628,103

G

nucleolar protein 4

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of NOL4 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NOL4 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:13,932,499...14,294,873
Ensembl chr18:14,207,303...14,569,677

G

neuropeptide FF receptor 2

increases expression
multiple interactions

ISO

belinostat results in increased expression of NPFFR2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPFFR2 mRNA

PMID:26272509 PMID:27188386

NCBI chr14:18,513,120...18,558,074
Ensembl chr14:18,797,234...18,842,186

G

natriuretic peptide receptor 3

increases expression

ISO

belinostat results in increased expression of NPR3 mRNA

NCBI chr 2:60,865,483...60,933,432
Ensembl chr 2:62,597,668...62,660,066

G

neuropeptide Y

increases expression
multiple interactions

ISO

belinostat results in increased expression of NPY mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NPY mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:80,212,111...80,219,310
Ensembl chr 4:80,212,111...80,219,310

G

NAD(P)H quinone dehydrogenase 1

multiple interactions
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NQO1 mRNA
belinostat results in increased expression of NQO1 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:52,205,374...52,220,267
Ensembl chr19:52,205,314...52,220,260

G

neuropilin 1

increases expression
multiple interactions

ISO

belinostat results in increased expression of NRP1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NRP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:73,256,557...73,411,705
Ensembl chr19:73,256,557...73,411,702

G

neurexin 2

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of NRXN2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NRXN2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:213,155,673...213,271,526
Ensembl chr 1:213,155,673...213,271,526

G

NOP2/Sun RNA methyltransferase family member 7

decreases expression

ISO

belinostat results in decreased expression of NSUN7 mRNA

NCBI chr14:41,878,562...41,935,238
Ensembl chr14:42,233,062...42,288,958

G

neurotrophic receptor tyrosine kinase 3

increases expression

ISO

belinostat results in increased expression of NTRK3 mRNA

NCBI chr 1:141,526,192...141,913,575
Ensembl chr 1:141,542,569...141,913,004

G

nucleobindin 2

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of NUCB2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of NUCB2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:180,185,121...180,221,644
Ensembl chr 1:180,199,551...180,230,116

G

nudix hydrolase 12

increases expression

ISO

belinostat results in increased expression of NUDT12 mRNA

NCBI chr 9:98,741,627...98,755,039
Ensembl chr 9:106,189,661...106,202,340

G

NACHT and WD repeat domain containing 2

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of NWD2 mRNA

NCBI chr14:44,480,049...44,671,417
Ensembl chr14:44,834,856...45,024,047

G

neurexophilin 2

decreases expression

ISO

belinostat results in decreased expression of NXPH2 mRNA

NCBI chr 3:5,986,175...5,988,525
Ensembl chr 3:26,153,756...26,391,876

G

OCIA domain containing 2

decreases expression

ISO

belinostat results in decreased expression of OCIAD2 mRNA

NCBI chr14:34,873,668...34,889,276
Ensembl chr14:35,225,255...35,243,311

G

ornithine decarboxylase 1

increases expression

ISO

belinostat results in increased expression of ODC1 mRNA

NCBI chr 6:40,329,831...40,336,444
Ensembl chr 6:46,058,463...46,065,146

G

8-oxoguanine DNA glycosylase

decreases expression

ISO

belinostat results in decreased expression of OGG1 mRNA; belinostat results in decreased expression of OGG1 protein

NCBI chr 4:146,474,701...146,481,959
Ensembl chr 4:148,030,349...148,037,604

G

olfactomedin 3

increases expression

ISO

belinostat results in increased expression of OLFM3 mRNA

NCBI chr 2:202,729,610...202,952,120
Ensembl chr 2:205,598,959...205,640,479

G

olfactomedin-like 3

increases expression
multiple interactions

ISO

belinostat results in increased expression of OLFML3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of OLFML3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:191,244,221...191,247,050
Ensembl chr 2:193,932,665...193,935,494

G

5-oxoprolinase (ATP-hydrolysing)

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of OPLAH mRNA

NCBI chr 7:108,011,472...108,051,751
Ensembl chr 7:109,891,405...109,915,979

G

proliferation-associated 2G4

decreases expression

ISO

belinostat results in decreased expression of PA2G4 mRNA

NCBI chr 7:984,795...992,264
Ensembl chr 7:1,569,327...1,576,802

G

poly (ADP-ribose) polymerase 1

increases cleavage
multiple interactions
increases expression

ISO

belinostat results in increased cleavage of PARP1 protein
Bortezomib promotes the reaction [belinostat results in increased cleavage of PARP1 protein]
belinostat results in increased expression of PARP1 mRNA; belinostat results in increased expression of PARP1 protein

PMID:18223231 PMID:25537862 PMID:29733868

NCBI chr13:94,839,484...94,871,295
Ensembl chr13:94,839,433...94,871,567

G

poly (ADP-ribose) polymerase family, member 9

decreases expression

ISO

belinostat results in decreased expression of PARP9 mRNA

NCBI chr11:78,286,282...78,320,409
Ensembl chr11:78,286,287...78,320,608

G

parvin, beta

decreases expression

ISO

belinostat results in decreased expression of PARVB mRNA

NCBI chr 7:115,360,254...115,445,767
Ensembl chr 7:117,240,029...117,325,748

G

paired box 3

increases expression
multiple interactions

ISO

belinostat results in increased expression of PAX3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:79,567,455...79,664,042
Ensembl chr 9:87,016,999...87,124,141

G

paired box 7

increases expression
multiple interactions

ISO

belinostat results in increased expression of PAX7 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PAX7 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:151,996,368...152,098,023
Ensembl chr 5:157,279,623...157,381,121

G

PBX homeobox 2

decreases expression

ISO

belinostat results in decreased expression of PBX2 mRNA

NCBI chr20:4,151,500...4,156,425
Ensembl chr20:4,156,107...4,161,827

G

protocadherin 10

increases expression
multiple interactions

ISO

belinostat results in increased expression of PCDH10 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PCDH10 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:128,617,212...128,683,354
Ensembl chr 2:130,553,425...130,613,407

G

protocadherin 7

decreases expression

ISO

belinostat results in decreased expression of PCDH7 mRNA

NCBI chr14:52,471,801...52,901,696
Ensembl chr14:56,687,725...57,112,665

G

protocadherin 8

increases expression

ISO

belinostat results in increased expression of PCDH8 mRNA

NCBI chr15:55,198,470...55,203,039
Ensembl chr15:61,607,521...61,612,097

G

proprotein convertase subtilisin/kexin type 9

decreases expression

ISO

belinostat results in decreased expression of PCSK9 mRNA

NCBI chr 5:126,440,102...126,462,507
Ensembl chr 5:126,440,102...126,462,507

G

phosphodiesterase 10A

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of PDE10A mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PDE10A mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:51,765,743...52,218,086
Ensembl chr 1:54,317,732...54,764,051

G

phosphodiesterase 7B

increases expression

ISO

belinostat results in increased expression of PDE7B mRNA

NCBI chr 1:15,174,001...15,493,267
Ensembl chr 1:17,002,286...17,312,456

G

platelet derived growth factor subunit A

multiple interactions
decreases expression
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDGFA mRNA
belinostat results in decreased expression of PDGFA mRNA
belinostat results in increased expression of PDGFA mRNA

PMID:26272509 PMID:27188386

NCBI chr12:20,759,366...20,780,337
Ensembl chr12:20,754,208...20,780,322

G

PDZ and LIM domain 1

multiple interactions
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDLIM1 mRNA
belinostat results in increased expression of PDLIM1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:239,042,372...239,091,074
Ensembl chr 1:248,991,818...249,047,379

G

podoplanin

increases expression
multiple interactions

ISO

belinostat results in increased expression of PDPN mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PDPN mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:160,884,995...160,919,112
Ensembl chr 5:160,884,993...160,925,637

G

paternally expressed 10

increases expression

ISO

belinostat results in increased expression of PEG10 mRNA

NCBI chr 4:32,842,441...32,855,639
Ensembl chr 4:33,817,190...33,819,166
Ensembl chr 4:33,817,190...33,819,166

G

peroxisomal biogenesis factor 13

increases expression

ISO

belinostat results in increased expression of PEX13 mRNA

NCBI chr14:101,804,673...101,822,367
Ensembl chr14:101,804,673...101,822,367

G

pleckstrin homology-like domain, family A, member 1

increases expression

ISO

belinostat results in increased expression of PHLDA1 mRNA

NCBI chr 7:48,853,690...48,855,894
Ensembl chr 7:48,853,260...48,857,542

G

pleckstrin homology-like domain, family A, member 2

increases expression
multiple interactions

ISO

belinostat results in increased expression of PHLDA2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PHLDA2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:198,696,897...198,699,292
Ensembl chr 1:208,126,302...208,127,920

G

piezo-type mechanosensitive ion channel component 1

multiple interactions
decreases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PIEZO1 mRNA
belinostat results in decreased expression of PIEZO1 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:67,453,120...67,515,347
Ensembl chr19:67,453,122...67,515,037

G

Pim-1 proto-oncogene, serine/threonine kinase

increases expression

ISO

belinostat results in increased expression of PIM1 mRNA

NCBI chr20:7,556,496...7,560,747
Ensembl chr20:7,556,113...7,561,764

G

pipecolic acid and sarcosine oxidase

increases expression
multiple interactions

ISO

belinostat results in increased expression of PIPOX mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PIPOX mRNA

PMID:26272509 PMID:27188386

NCBI chr10:62,769,874...62,783,484
Ensembl chr10:63,267,972...63,282,273

G

paired-like homeodomain 2

increases expression

ISO

belinostat results in increased expression of PITX2 mRNA

NCBI chr 2:220,391,417...220,411,588
Ensembl chr 2:220,391,888...220,411,591

G

protein kinase domain containing, cytoplasmic

increases expression
multiple interactions

ISO

belinostat results in increased expression of PKDCC mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PKDCC mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:11,455,686...11,465,002
Ensembl chr 6:17,208,171...17,218,042

G

phospholipase A2 group IIA

increases expression
multiple interactions

ISO

belinostat results in increased expression of PLA2G2A mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G2A mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:156,359,725...156,362,302
Ensembl chr 5:156,359,725...156,362,297

G

phospholipase A2 group 4A

increases expression
multiple interactions

ISO

belinostat results in increased expression of PLA2G4A mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLA2G4A mRNA

PMID:26272509 PMID:27188386

NCBI chr13:64,427,921...64,572,352
Ensembl chr13:64,427,916...64,589,641

G

phospholipase A and acyltransferase 3

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAAT3 mRNA

NCBI chr 1:214,211,755...214,245,551
Ensembl chr 1:214,211,791...214,246,763

G

plasminogen activator, urokinase

increases expression
multiple interactions

ISO

belinostat results in increased expression of PLAU mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PLAU mRNA

PMID:26272509 PMID:27188386

NCBI chr15:3,505,485...3,511,987
Ensembl chr15:3,505,487...3,512,030

G

phospholipase C, epsilon 1

decreases expression

ISO

belinostat results in decreased expression of PLCE1 mRNA

NCBI chr 1:245,655,855...245,964,966
Ensembl chr 1:245,657,080...245,963,828

G

phospholipase D family, member 5

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of PLD5 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLD5 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:87,895,694...88,232,868
Ensembl chr13:90,428,490...90,783,066

G

pleckstrin homology domain containing A2

decreases expression

ISO

belinostat results in decreased expression of PLEKHA2 mRNA

NCBI chr16:66,938,684...67,000,661
Ensembl chr16:73,641,344...73,703,087

G

plasminogen

decreases expression

ISO

belinostat results in decreased expression of PLG mRNA

NCBI chr 1:50,872,927...50,915,406
Ensembl chr 1:50,872,926...50,917,320

G

phospholipid phosphatase 5

decreases expression

ISO

belinostat results in decreased expression of PLPP5 mRNA

NCBI chr16:66,349,483...66,353,887
Ensembl chr16:73,052,204...73,056,643

G

plexin C1

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of PLXNC1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PLXNC1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:29,390,038...29,543,985
Ensembl chr 7:31,276,978...31,431,092

G

pancreatic lipase related protein 2

decreases expression

ISO

belinostat results in decreased expression of PNLIPRP2 mRNA

NCBI chr 1:257,897,766...257,916,434
Ensembl chr 1:267,883,906...267,902,572

G

PNMA family member 2

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of PNMA2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PNMA2 mRNA

PMID:26272509 PMID:27188386

NCBI chr15:41,111,942...41,119,649
Ensembl chr15:45,286,304...45,298,080

G

podocalyxin-like

increases expression
multiple interactions

ISO

belinostat results in increased expression of PODXL mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PODXL mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:60,135,124...60,181,829
Ensembl chr 4:61,102,419...61,149,789

G

RNA polymerase III subunit G

increases expression
multiple interactions

ISO

belinostat results in increased expression of POLR3G mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POLR3G mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:11,945,215...11,986,125
Ensembl chr 2:13,680,895...13,721,802

G

POU class 2 homeobox 3

multiple interactions
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of POU2F3 mRNA
belinostat results in increased expression of POU2F3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:43,495,408...43,577,795
Ensembl chr 8:52,392,497...52,474,756

G

POU class 5 homeobox 1

increases expression

ISO

belinostat results in increased expression of POU5F1 mRNA

NCBI chr20:3,223,128...3,227,891
Ensembl chr20:3,227,837...3,232,598

G

POU class 6 homeobox 2

increases expression

ISO

belinostat results in increased expression of POU6F2 mRNA

NCBI chr17:46,472,182...46,886,796
Ensembl chr17:51,167,771...51,616,597

G

PPARG coactivator 1 beta

increases expression
multiple interactions

ISO

belinostat results in increased expression of PPARGC1B mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPARGC1B mRNA

PMID:26272509 PMID:27188386

NCBI chr18:54,758,891...54,861,103
Ensembl chr18:57,029,275...57,131,466

G

peptidylprolyl isomerase C

increases expression
multiple interactions

ISO

belinostat results in increased expression of PPIC mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPIC mRNA

PMID:26272509 PMID:27188386

NCBI chr18:46,842,410...46,855,016
Ensembl chr18:49,040,692...49,053,466

G

protein phosphatase, Mg2+/Mn2+ dependent, 1K

increases expression
multiple interactions

ISO

belinostat results in increased expression of PPM1K mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPM1K mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:87,612,198...87,638,993
Ensembl chr 4:88,942,386...88,969,136

G

protein phosphatase 1, regulatory subunit 15A

increases expression

ISO

belinostat results in increased expression of PPP1R15A mRNA

NCBI chr 1:96,000,053...96,003,128
Ensembl chr 1:105,136,525...105,139,774

G

protein phosphatase 1, regulatory subunit 3B

increases expression
multiple interactions

ISO

belinostat results in increased expression of PPP1R3B mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PPP1R3B mRNA

PMID:26272509 PMID:27188386

NCBI chr16:56,830,011...56,842,395
Ensembl chr16:63,532,842...63,549,997

G

protein phosphatase 4, regulatory subunit 4

increases expression

ISO

belinostat results in increased expression of PPP4R4 mRNA

NCBI chr 6:122,663,172...122,753,988
Ensembl chr 6:128,427,893...128,528,039

G

PR/SET domain 14

increases expression
multiple interactions

ISO

belinostat results in increased expression of PRDM14 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRDM14 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:6,082,163...6,092,712
Ensembl chr 5:10,864,137...10,876,666

G

proline rich membrane anchor 1

decreases expression

ISO

belinostat results in decreased expression of PRIMA1 mRNA

NCBI chr 6:122,338,365...122,390,955
Ensembl chr 6:128,103,175...128,154,865

G

protein kinase cAMP-activated catalytic subunit alpha

increases expression
multiple interactions

ISO

belinostat results in increased expression of PRKACA mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRKACA mRNA

PMID:26272509 PMID:27188386

NCBI chr19:41,059,843...41,083,189
Ensembl chr19:41,059,843...41,086,494

G

proline rich 15

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of PRR15 mRNA

NCBI chr 4:83,432,002...83,435,582
Ensembl chr 4:84,761,523...84,768,442

G

serine protease 23

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of PRSS23 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of PRSS23 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:143,402,725...143,422,182
Ensembl chr 1:152,813,670...152,947,871

G

phosphoseryl-tRNA kinase

decreases expression

ISO

belinostat results in decreased expression of PSTK mRNA

NCBI chr 1:186,157,730...186,168,145
Ensembl chr 1:195,587,890...195,604,035

G

protein tyrosine phosphatase 4A3

decreases expression

ISO

belinostat results in decreased expression of PTP4A3 mRNA

NCBI chr 7:105,650,640...105,660,921
Ensembl chr 7:107,541,047...107,549,949

G

protein tyrosine phosphatase, non-receptor type 3

decreases expression

ISO

belinostat results in decreased expression of PTPN3 mRNA

NCBI chr 5:71,908,520...72,027,323
Ensembl chr 5:76,703,687...76,860,470

G

protein tyrosine phosphatase, non-receptor type 5

decreases expression

ISO

belinostat results in decreased expression of PTPN5 mRNA

NCBI chr 1:97,620,638...97,681,186
Ensembl chr 1:106,756,896...106,816,828

G

pentraxin 3

decreases expression

ISO

belinostat results in decreased expression of PTX3 mRNA

NCBI chr 2:150,487,513...150,493,323
Ensembl chr 2:152,781,955...152,803,372

G

pyridine nucleotide-disulphide oxidoreductase domain 2

decreases expression

ISO

belinostat results in decreased expression of PYROXD2 mRNA

NCBI chr 1:241,523,278...241,549,083
Ensembl chr 1:251,471,849...251,498,008

G

RAB29, member RAS oncogene family

increases expression

ISO

belinostat results in increased expression of RAB29 mRNA

NCBI chr13:43,307,757...43,313,420
Ensembl chr13:45,859,961...45,865,610

G

RAB33A, member RAS oncogene family

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB33A mRNA

NCBI chr X:127,694,219...127,706,378
Ensembl chr X:132,572,148...132,584,254

G

RAB3C, member RAS oncogene family

increases expression
multiple interactions

ISO

belinostat results in increased expression of RAB3C mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RAB3C mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:41,627,720...41,843,541
Ensembl chr 2:43,361,093...43,577,022

G

RAB3A interacting protein

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAB3IP mRNA

NCBI chr 7:52,531,461...52,575,295
Ensembl chr 7:54,418,358...54,447,000

G

RAB GTPase activating protein 1-like

increases expression
multiple interactions

ISO

belinostat results in increased expression of RABGAP1L mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RABGAP1L mRNA

PMID:26272509 PMID:27188386

NCBI chr13:74,997,542...75,593,240
Ensembl chr13:74,997,542...75,533,816

G

Rac family small GTPase 1

decreases expression

ISO

belinostat results in decreased expression of RAC1 mRNA

NCBI chr12:16,150,411...16,170,864
Ensembl chr12:16,128,649...16,172,109

G

RAD17 checkpoint clamp loader component

decreases expression

ISO

belinostat results in decreased expression of RAD17 mRNA

NCBI chr 2:31,764,260...31,794,542
Ensembl chr 2:33,498,336...33,528,144

G

RAD18 E3 ubiquitin protein ligase

decreases expression

ISO

belinostat results in decreased expression of RAD18 mRNA

NCBI chr 4:145,735,654...145,821,102
Ensembl chr 4:147,291,276...147,376,869

G

RAD51 paralog C

decreases expression

ISO

belinostat results in decreased expression of RAD51C mRNA; belinostat results in decreased expression of RAD51C protein

NCBI chr10:72,205,032...72,231,643
Ensembl chr10:72,702,299...72,729,143

G

RAD9 checkpoint clamp component A

decreases expression

ISO

belinostat results in decreased expression of RAD9A mRNA

NCBI chr 1:210,917,970...210,983,038
Ensembl chr 1:210,917,970...210,925,161

G

RAN, member RAS oncogene family

decreases expression

ISO

belinostat results in decreased expression of RAN mRNA

NCBI chr12:33,311,155...33,314,339
Ensembl chr12:33,311,158...33,314,317

G

retinoic acid receptor responder 1

decreases expression

ISO

belinostat results in decreased expression of RARRES1 mRNA

NCBI chr 2:154,059,761...154,094,021
Ensembl chr 2:154,059,761...154,094,024

G

retinoic acid receptor responder 2

increases expression
multiple interactions

ISO

belinostat results in increased expression of RARRES2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RARRES2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:78,853,450...78,856,652
Ensembl chr 4:78,853,453...78,856,457

G

RAS and EF hand domain containing

increases expression

ISO

belinostat results in increased expression of RASEF mRNA

NCBI chr 5:87,548,908...87,619,286
Ensembl chr 5:92,595,148...92,666,117

G

retina and anterior neural fold homeobox

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of RAX mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RAX mRNA

PMID:26272509 PMID:27188386

NCBI chr18:61,733,322...61,737,444
Ensembl chr18:61,733,322...61,737,444

G

RNA binding fox-1 homolog 3

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of RBFOX3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RBFOX3 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:103,720,355...104,157,277
Ensembl chr10:104,218,940...104,551,945

G

RCC1 and BTB domain containing protein 2

decreases expression

ISO

belinostat results in decreased expression of RCBTB2 mRNA

NCBI chr15:48,319,809...48,364,441
Ensembl chr15:54,729,332...54,793,313

G

regulator of chromosome condensation 2

decreases expression

ISO

belinostat results in decreased expression of RCC2 mRNA

NCBI chr 5:152,994,406...153,017,223
Ensembl chr 5:158,277,476...158,300,294

G

RELA proto-oncogene, NF-kB subunit

multiple interactions
increases acetylation

ISO

Bortezomib inhibits the reaction [belinostat results in increased acetylation of RELA protein]

NCBI chr 1:212,354,336...212,364,815
Ensembl chr 1:212,333,035...212,364,817

G

reelin

increases expression

ISO

belinostat results in increased expression of RELN mRNA

NCBI chr 4:13,628,440...14,055,201
Ensembl chr 4:13,628,399...14,055,162

G

REV1, DNA directed polymerase

decreases expression

ISO

belinostat results in decreased expression of REV1 mRNA

NCBI chr 9:40,278,100...40,351,764
Ensembl chr 9:47,773,907...47,847,332

G

ras homolog family member B

increases expression
multiple interactions

ISO

belinostat results in increased expression of RHOB mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RHOB mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:37,083,030...37,085,204
Ensembl chr 6:37,075,015...37,112,772

G

ring finger protein 144B

increases expression
multiple interactions

ISO

belinostat results in increased expression of RNF144B mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF144B mRNA

PMID:26272509 PMID:27188386

NCBI chr17:17,431,271...17,580,687
Ensembl chr17:17,639,079...17,769,037

G

ring finger protein 150

increases expression
multiple interactions

ISO

belinostat results in increased expression of RNF150 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF150 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:25,006,978...25,229,273
Ensembl chr19:41,912,276...42,133,217

G

ring finger protein 180

decreases expression

ISO

belinostat results in decreased expression of RNF180 mRNA

NCBI chr 2:36,330,285...36,511,168
Ensembl chr 2:38,064,031...38,265,358

G

ring finger protein 217

multiple interactions
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RNF217 mRNA
belinostat results in increased expression of RNF217 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:26,016,668...26,108,736
Ensembl chr 1:27,835,148...27,928,044

G

roundabout guidance receptor 2

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of ROBO2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ROBO2 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:26,015,919...27,583,750
Ensembl chr11:26,015,919...26,876,185

G

rabphilin 3A-like (without C2 domains)

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RPH3AL mRNA

NCBI chr10:61,188,288...61,331,591
Ensembl chr10:61,188,293...61,300,145

G

ribosomal L1 domain containing 1

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RSL1D1 mRNA

NCBI chr10:4,931,839...4,943,726
Ensembl chr10:4,904,792...4,946,566

G

RT1 class II, locus DMb

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of HLA-DMB mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of HLA-DMB mRNA

PMID:26272509 PMID:27188386

NCBI chr20:4,693,102...4,700,340
Ensembl chr20:4,695,010...4,702,246

G

RT1 class II, locus Ha

decreases expression

ISO

belinostat results in decreased expression of HLA-DPA1 mRNA

NCBI chr20:4,760,631...4,770,662
Ensembl chr20:4,763,033...4,772,141

G

reticulon 1

multiple interactions
decreases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of RTN1 mRNA
belinostat results in decreased expression of RTN1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:96,499,137...96,719,340
Ensembl chr 6:96,499,134...96,719,340

G

receptor (chemosensory) transporter protein 1

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RTP1 mRNA

NCBI chr11:77,422,982...77,425,498
Ensembl chr11:90,927,633...90,930,149

G

RUNX1 partner transcriptional co-repressor 1

increases expression
multiple interactions

ISO

belinostat results in increased expression of RUNX1T1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of RUNX1T1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:27,187,674...27,338,070
Ensembl chr 5:31,984,855...32,132,855

G

S100 calcium binding protein A10

increases expression
multiple interactions

ISO

belinostat results in increased expression of S100A10 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of S100A10 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:181,904,454...181,913,101
Ensembl chr 2:181,904,261...181,913,103

G

sphingosine-1-phosphate receptor 3

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of S1PR3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of S1PR3 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:13,781,050...13,794,408
Ensembl chr17:13,928,444...13,947,197

G

spermidine/spermine N1-acetyl transferase 1

multiple interactions
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SAT1 mRNA
belinostat results in increased expression of SAT1 mRNA

PMID:19606018 PMID:26272509 PMID:27188386

NCBI chr X:40,158,354...40,161,641
Ensembl chr X:44,006,781...44,011,374

G

secretogranin III

increases expression
multiple interactions

ISO

belinostat results in increased expression of SCG3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCG3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:76,399,777...76,442,015
Ensembl chr 8:85,280,253...85,361,874

G

secretoglobin, family 3A, member 2

multiple interactions
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCGB3A2 mRNA
belinostat results in increased expression of SCGB3A2 mRNA

PMID:26272509 PMID:27188386

NCBI chr18:35,932,840...35,935,762
Ensembl chr18:36,183,698...36,186,742

G

sodium channel and clathrin linker 1

increases expression

ISO

belinostat results in increased expression of SCLT1 mRNA

NCBI chr 2:124,605,445...124,763,964
Ensembl chr 2:126,533,560...126,691,971

G

Scm polycomb group protein like 1

multiple interactions
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCML1 mRNA
belinostat results in increased expression of SCML1 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:32,893,100...32,912,686
Ensembl chr X:36,526,068...36,544,450

G

sodium channel epithelial 1 subunit alpha

increases expression
multiple interactions

ISO

belinostat results in increased expression of SCNN1A mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SCNN1A mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:159,809,187...159,832,409
Ensembl chr 4:159,809,170...159,832,405

G

serine dehydratase-like

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of SDSL mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SDSL mRNA

PMID:26272509 PMID:27188386

NCBI chr12:36,099,693...36,109,914
Ensembl chr12:41,760,252...41,770,465

G

semaphorin 3B

decreases expression

ISO

belinostat results in decreased expression of SEMA3B mRNA

NCBI chr 8:108,271,663...108,280,326
Ensembl chr 8:117,150,589...117,157,658

G

semaphorin 3C

increases expression

ISO

belinostat results in increased expression of SEMA3C mRNA

NCBI chr 4:17,583,212...17,747,234
Ensembl chr 4:18,538,454...18,701,740

G

semaphorin 3E

increases expression
multiple interactions

ISO

belinostat results in increased expression of SEMA3E mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEMA3E mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:21,252,686...21,510,449
Ensembl chr 4:21,210,734...21,510,374

G

semaphorin 3F

decreases expression

ISO

belinostat results in decreased expression of SEMA3F mRNA

NCBI chr 8:108,357,629...108,386,569
Ensembl chr 8:117,236,269...117,265,206

G

semaphorin 6D

decreases expression

ISO

belinostat results in decreased expression of SEMA6D mRNA

NCBI chr 3:111,883,415...111,941,100
Ensembl chr 3:132,337,343...132,394,584

G

septin 6

increases expression
multiple interactions

ISO

belinostat results in increased expression of SEPTIN6 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEPTIN6 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:116,153,255...116,230,334
Ensembl chr X:121,018,944...121,095,792

G

serpin family A member 1

decreases expression

ISO

belinostat results in decreased expression of SERPINA1 mRNA

NCBI chr 6:122,866,314...122,888,339
Ensembl chr 6:128,619,382...128,660,703

G

serpin family A member 7

decreases expression

ISO

belinostat results in decreased expression of SERPINA7 mRNA

NCBI chr X:107,452,044...107,510,958
Ensembl chr X:107,452,044...107,457,681

G

serpin family B member 1A

decreases expression

ISO

belinostat results in decreased expression of SERPINB1 mRNA

NCBI chr17:31,590,695...31,599,102
Ensembl chr17:31,799,415...31,808,166

G

serpin family B member 9

increases expression
multiple interactions

ISO

belinostat results in increased expression of SERPINB9 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINB9 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:31,628,887...31,652,003
Ensembl chr17:31,629,392...31,651,974

G

serpin family I member 1

increases expression
multiple interactions

ISO

belinostat results in increased expression of SERPINI1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SERPINI1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:160,346,403...160,433,135
Ensembl chr 2:162,645,350...162,731,740

G

sestrin 3

increases expression

ISO

belinostat results in increased expression of SESN3 mRNA

NCBI chr 8:19,415,307...19,470,943
Ensembl chr 8:19,415,347...19,466,904

G

seizure related 6 homolog

increases expression
multiple interactions

ISO

belinostat results in increased expression of SEZ6 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SEZ6 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:62,818,931...62,868,686
Ensembl chr10:63,316,953...63,366,723

G

Scm-like with four mbt domains 2

increases expression
multiple interactions

ISO

belinostat results in increased expression of SFMBT2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SFMBT2 mRNA

PMID:26272509 PMID:27188386

NCBI chr17:67,934,296...68,128,905
Ensembl chr17:72,845,708...73,032,172

G

serum/glucocorticoid regulated kinase family, member 3

increases expression
multiple interactions

ISO

belinostat results in increased expression of SGK3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SGK3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:14,128,628...14,255,099
Ensembl chr 5:14,126,257...14,198,331

G

SHC adaptor protein 3

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHC3 mRNA

NCBI chr17:13,652,247...13,772,710
Ensembl chr17:13,803,781...13,924,433

G

shisa like 1

multiple interactions
decreases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SHISAL1 mRNA
belinostat results in decreased expression of SHISAL1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:115,506,947...115,611,518

G

shroom family member 1

decreases expression

ISO

belinostat results in decreased expression of SHROOM1 mRNA

NCBI chr10:37,621,149...37,631,895
Ensembl chr10:38,122,500...38,132,435

G

sialic acid acetylesterase

increases expression

ISO

belinostat results in increased expression of SIAE mRNA

NCBI chr 8:37,318,724...37,354,004
Ensembl chr 8:45,507,326...45,542,740

G

SIX homeobox 3

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of SIX3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SIX3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:14,791,937...14,796,365
Ensembl chr 6:14,789,354...14,804,175

G

Six6 opposite strand transcript 1

multiple interactions
decreases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of C14ORF39 mRNA
belinostat results in decreased expression of C14ORF39 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:91,579,185...91,615,183
Ensembl chr 6:97,314,712...97,351,171

G

src kinase associated phosphoprotein 2

increases expression

ISO

belinostat results in increased expression of SKAP2 mRNA

NCBI chr 4:80,948,832...81,100,900
Ensembl chr 4:82,263,709...82,432,886

G

solute carrier family 16, member 14

multiple interactions
decreases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC16A14 mRNA
belinostat results in decreased expression of SLC16A14 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:86,110,066...86,137,546
Ensembl chr 9:93,558,144...93,585,396

G

solute carrier family 1 member 3

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC1A3 mRNA

NCBI chr 2:59,482,707...59,557,808
Ensembl chr 2:59,482,709...59,557,808

G

solute carrier family 25 member 21

decreases expression

ISO

belinostat results in decreased expression of SLC25A21 mRNA

NCBI chr 6:79,938,480...80,437,937
Ensembl chr 6:79,938,480...80,437,502

G

solute carrier family 27 member 2

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC27A2 mRNA

NCBI chr 3:134,258,101...134,295,581
Ensembl chr 3:134,258,101...134,295,581

G

solute carrier family 35, member D3

increases expression
multiple interactions

ISO

belinostat results in increased expression of SLC35D3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC35D3 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:14,565,482...14,573,581
Ensembl chr 1:16,389,308...16,392,780

G

solute carrier family 35, member F3

decreases expression

ISO

belinostat results in decreased expression of SLC35F3 mRNA

NCBI chr19:54,102,811...54,371,765
Ensembl chr19:71,000,265...71,269,517

G

solute carrier family 38, member 4

increases expression
multiple interactions

ISO

belinostat results in increased expression of SLC38A4 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC38A4 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:128,142,866...128,203,000
Ensembl chr 7:130,023,980...130,082,097

G

solute carrier family 38, member 6

increases expression
multiple interactions

ISO

belinostat results in increased expression of SLC38A6 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLC38A6 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:91,987,652...92,076,416
Ensembl chr 6:97,723,471...97,785,791

G

solute carrier family 43 member 1

increases expression

ISO

belinostat results in increased expression of SLC43A1 mRNA

NCBI chr 3:69,920,586...69,946,768
Ensembl chr 3:90,327,149...90,353,438

G

solute carrier family 44, member 3

decreases expression

ISO

belinostat results in decreased expression of SLC44A3 mRNA

NCBI chr 2:209,552,138...209,628,182
Ensembl chr 2:212,236,853...212,312,982

G

solute carrier family 6 member 2

increases expression

ISO

belinostat results in increased expression of SLC6A2 mRNA

NCBI chr19:30,183,289...30,228,292
Ensembl chr19:30,183,383...30,223,348

G

solute carrier family 7 member 11

decreases expression

ISO

belinostat results in decreased expression of SLC7A11 mRNA

NCBI chr 2:136,532,912...136,668,560
Ensembl chr 2:136,532,246...136,695,695

G

solute carrier family 9 member B2

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of SLC9B2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SLC9B2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:226,400,358...226,435,039
Ensembl chr 2:226,410,263...226,435,030

G

solute carrier organic anion transporter family, member 4C1

increases expression
multiple interactions

ISO

belinostat results in increased expression of SLCO4C1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLCO4C1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:104,624,802...104,676,462
Ensembl chr 9:104,624,802...104,676,462

G

schlafen family member 4

increases expression

ISO

belinostat results in increased expression of SLFN12 mRNA

NCBI chr10:67,994,601...68,018,141

G

slit guidance ligand 1

increases expression
multiple interactions

ISO

belinostat results in increased expression of SLIT1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SLIT1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:250,358,917...250,507,476
Ensembl chr 1:250,358,919...250,507,476

G

slit guidance ligand 2

increases expression

ISO

belinostat results in increased expression of SLIT2 mRNA

NCBI chr14:66,829,661...67,168,517
Ensembl chr14:66,829,661...67,167,146

G

SWI/SNF related BAF chromatin remodeling complex subunit ATPase 2

increases expression
multiple interactions

ISO

belinostat results in increased expression of SMARCA2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SMARCA2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:233,617,277...233,784,908
Ensembl chr 1:233,617,366...233,784,869

G

SPARC related modular calcium binding 1

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of SMOC1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SMOC1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:100,701,330...100,897,441
Ensembl chr 6:106,432,603...106,593,956

G

snail family transcriptional repressor 2

increases expression
multiple interactions

ISO

belinostat results in increased expression of SNAI2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAI2 mRNA

PMID:26272509 PMID:27188386

NCBI chr11:99,686,934...99,690,349
Ensembl chr11:99,686,934...99,690,349

G

synaptosome associated protein 25

increases expression
multiple interactions

ISO

belinostat results in increased expression of SNAP25 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SNAP25 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:144,494,579...144,576,449
Ensembl chr 3:144,494,595...144,576,448

G

sorting nexin 10

decreases expression

ISO

belinostat results in decreased expression of SNX10 mRNA

NCBI chr 4:80,612,648...80,677,005
Ensembl chr 4:81,943,287...82,007,651

G

suppressor of cytokine signaling 3

decreases expression

ISO

belinostat results in decreased expression of SOCS3 mRNA

NCBI chr10:103,692,579...103,695,975
Ensembl chr10:103,690,976...103,704,825

G

SRY-box transcription factor 6

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of SOX6 mRNA

NCBI chr 1:169,723,306...170,334,846
Ensembl chr 1:179,163,566...179,711,727

G

SRY-box transcription factor 8

increases expression
multiple interactions

ISO

belinostat results in increased expression of SOX8 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SOX8 mRNA

PMID:26272509 PMID:27188386

NCBI chr10:14,584,829...14,589,818
Ensembl chr10:15,089,357...15,094,345

G

serine peptidase inhibitor, Kazal type 2

increases expression

ISO

belinostat results in increased expression of SPINK2 mRNA

NCBI chr14:30,967,682...30,974,326
Ensembl chr14:31,322,010...31,328,622

G

spexin hormone

decreases expression

ISO

belinostat results in decreased expression of SPX mRNA

NCBI chr 4:175,356,044...175,362,082
Ensembl chr 4:177,087,256...177,093,091

G

sarcospan

decreases expression

ISO

belinostat results in decreased expression of SSPN mRNA

NCBI chr 4:178,890,030...178,946,267
Ensembl chr 4:180,627,848...180,662,284

G

somatostatin

increases expression

ISO

belinostat results in increased expression of SST mRNA

NCBI chr11:76,956,896...76,958,173
Ensembl chr11:90,461,546...90,462,823

G

stanniocalcin 2

decreases expression

ISO

belinostat results in decreased expression of STC2 mRNA

NCBI chr10:16,251,046...16,260,815
Ensembl chr10:16,755,267...16,767,447

G

serine/threonine kinase 32A

decreases expression

ISO

belinostat results in decreased expression of STK32A mRNA

NCBI chr18:35,258,865...35,374,985
Ensembl chr18:35,509,982...35,628,985

G

stathmin 2

increases expression
multiple interactions

ISO

belinostat results in increased expression of STMN2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of STMN2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:95,112,017...95,159,642
Ensembl chr 2:95,112,019...95,159,335

G

sulfotransferase family 1C member 2A

increases expression
multiple interactions
decreases expression

ISO

belinostat results in increased expression of SULT1C2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SULT1C2 mRNA
belinostat results in decreased expression of SULT1C2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:6,873,697...6,904,736
Ensembl chr 9:7,066,905...7,244,132

G

sulfotransferase family 2A member 1

decreases expression

ISO

belinostat results in decreased expression of SULT2A1 mRNA

NCBI chr 1:75,451,178...75,508,113

G

sushi domain containing 1

decreases expression

ISO

belinostat results in decreased expression of SUSD1 mRNA

NCBI chr 5:74,157,653...74,281,171
Ensembl chr 5:78,952,781...79,070,781

G

synaptojanin 2

decreases expression

ISO

belinostat results in decreased expression of SYNJ2 mRNA

NCBI chr 1:46,518,594...46,621,919
Ensembl chr 1:48,923,737...49,038,650

G

synemin

decreases expression

ISO

belinostat results in decreased expression of SYNM mRNA

NCBI chr 1:121,333,712...121,363,652
Ensembl chr 1:130,743,897...130,773,824

G

transforming, acidic coiled-coil containing protein 1

increases expression

ISO

belinostat results in increased expression of TACC1 mRNA

NCBI chr16:73,515,016...73,598,395
Ensembl chr16:73,514,889...73,598,394

G

tumor-associated calcium signal transducer 2

multiple interactions
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TACSTD2 mRNA
belinostat results in increased expression of TACSTD2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 4:98,037,620...98,039,320
Ensembl chr 4:98,033,251...98,039,323

G

TAFA chemokine like family member 2

increases expression
multiple interactions

ISO

belinostat results in increased expression of TAFA2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TAFA2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 7:58,942,598...59,418,640
Ensembl chr 7:60,891,958...61,303,869

G

TAO kinase 3

increases expression

ISO

belinostat results in increased expression of TAOK3 mRNA

NCBI chr12:39,312,354...39,473,656
Ensembl chr12:44,973,180...45,134,439

G

tandem C2 domains, nuclear

increases expression
multiple interactions

ISO

belinostat results in increased expression of TC2N mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TC2N mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:120,761,112...120,856,835
Ensembl chr 6:126,526,009...126,614,215

G

T cell activation inhibitor, mitochondrial

decreases expression

ISO

belinostat results in decreased expression of TCAIM mRNA

NCBI chr 8:122,414,827...122,446,105
Ensembl chr 8:131,292,351...131,323,571

G

transcription factor AP-2 alpha

increases expression
multiple interactions

ISO

belinostat results in increased expression of TFAP2A mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2A mRNA

PMID:26272509 PMID:27188386

NCBI chr17:24,230,064...24,253,219
Ensembl chr17:24,229,910...24,253,219

G

transcription factor AP-2 beta

increases expression
multiple interactions

ISO

belinostat results in increased expression of TFAP2B mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2B mRNA

PMID:26272509 PMID:27188386

NCBI chr 9:21,786,251...21,816,054
Ensembl chr 9:29,282,825...29,312,568

G

transcription factor AP-2 gamma

increases expression
multiple interactions

ISO

belinostat results in increased expression of TFAP2C mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFAP2C mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:181,733,524...181,742,412
Ensembl chr 3:181,733,419...181,741,404

G

trefoil factor 1

decreases expression

ISO

belinostat results in decreased expression of TFF1 mRNA

NCBI chr20:9,237,095...9,240,956
Ensembl chr20:9,237,095...9,240,956

G

trefoil factor 2

decreases expression

ISO

belinostat results in decreased expression of TFF2 mRNA

NCBI chr20:9,215,750...9,219,619
Ensembl chr20:9,217,121...9,220,979

G

tissue factor pathway inhibitor

increases expression
multiple interactions

ISO

belinostat results in increased expression of TFPI mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TFPI mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:89,939,862...89,989,253
Ensembl chr 3:89,939,868...89,980,742

G

transforming growth factor, beta 2

increases expression

ISO

belinostat results in increased expression of TGFB2 mRNA

NCBI chr13:100,691,540...100,793,227
Ensembl chr13:100,692,953...100,792,856

G

thyroid hormone receptor beta

increases expression
multiple interactions

ISO

belinostat results in increased expression of THRB mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of THRB mRNA

PMID:26272509 PMID:27188386

NCBI chr15:10,115,954...10,465,231
Ensembl chr15:10,115,954...10,313,680

G

TIMP metallopeptidase inhibitor 3

decreases expression

ISO

belinostat results in decreased expression of TIMP3 mRNA

NCBI chr 7:17,520,827...17,571,850
Ensembl chr 7:19,409,631...19,459,547

G

transmembrane protein 220

decreases expression

ISO

belinostat results in decreased expression of TMEM220 mRNA

NCBI chr10:51,719,777...51,728,792
Ensembl chr10:52,218,760...52,227,783

G

transmembrane protein 221

decreases expression

ISO

belinostat results in decreased expression of TMEM221 mRNA

NCBI chr16:18,253,622...18,271,094
Ensembl chr16:18,295,931...18,305,246

G

transmembrane protein 30B

multiple interactions
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM30B mRNA
belinostat results in increased expression of TMEM30B mRNA

PMID:26272509 PMID:27188386

NCBI chr 6:92,251,626...92,254,702
Ensembl chr 6:97,987,130...97,991,170

G

transmembrane protein 44

decreases expression

ISO

belinostat results in decreased expression of TMEM44 mRNA

NCBI chr11:70,181,120...70,216,958
Ensembl chr11:83,686,015...83,721,859

G

transmembrane protein 51

decreases expression

ISO

belinostat results in decreased expression of TMEM51 mRNA

NCBI chr 5:154,325,853...154,375,882
Ensembl chr 5:159,608,866...159,658,891

G

transmembrane protein 64

increases expression
multiple interactions

ISO

belinostat results in increased expression of TMEM64 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TMEM64 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:28,698,947...28,745,384
Ensembl chr 5:33,496,032...33,542,389

G

thiol methyltransferase 1B

decreases expression

ISO

belinostat results in decreased expression of TMT1B mRNA

NCBI chr 7:1,388,876...1,391,526
Ensembl chr 7:1,973,337...1,975,980

G

tenascin C

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of TNC mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TNC mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:82,391,340...82,476,197
Ensembl chr 5:82,391,340...82,476,131

G

TNF superfamily member 11

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNFSF11 mRNA

NCBI chr15:60,083,008...60,114,479
Ensembl chr15:60,083,008...60,114,479

G

TRAF2 and NCK interacting kinase

increases expression
multiple interactions

ISO

belinostat results in increased expression of TNIK mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNIK mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:111,184,352...111,587,993
Ensembl chr 2:113,112,938...113,511,339

G

tenascin N

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TNN mRNA

NCBI chr13:72,319,160...72,386,362
Ensembl chr13:74,852,586...74,919,789

G

TOX high mobility group box family member 2

decreases expression
multiple interactions

ISO

belinostat results in decreased expression of TOX2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of TOX2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:151,853,294...151,980,086
Ensembl chr 3:172,272,736...172,400,233

G

tumor protein p53

decreases expression

ISO

belinostat results in decreased expression of TP53 mRNA
belinostat results in decreased expression of TRP53 mRNA; belinostat results in decreased expression of TRP53 protein

PMID:19606018 PMID:29733868

NCBI chr10:54,798,871...54,810,300
Ensembl chr10:54,798,851...54,810,299

G

TPD52 like 1

increases expression
multiple interactions

ISO

belinostat results in increased expression of TPD52L1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TPD52L1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:26,172,038...26,290,704
Ensembl chr 1:27,991,131...28,110,158

G

TPX2, microtubule nucleation factor

decreases expression

ISO

belinostat results in decreased expression of TPX2 mRNA

NCBI chr 3:161,778,709...161,820,941
Ensembl chr 3:161,778,742...161,820,724

G

tribbles pseudokinase 3

decreases expression

ISO

belinostat results in decreased expression of TRIB3 mRNA

NCBI chr 3:161,269,939...161,275,533
Ensembl chr 3:161,269,955...161,274,802

G

TMF1-regulated nuclear protein 1

increases expression
multiple interactions

ISO

belinostat results in increased expression of TRNP1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TRNP1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 5:145,706,427...145,713,279
Ensembl chr 5:150,989,973...150,997,277

G

tetratricopeptide repeat domain 29

increases expression
multiple interactions

ISO

belinostat results in increased expression of TTC29 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of TTC29 mRNA

PMID:26272509 PMID:27188386

NCBI chr19:29,531,707...29,750,635
Ensembl chr19:46,424,935...46,654,870

G

tubulin, alpha 1A

affects expression

ISO

belinostat affects the expression of TUBA1A mRNA

NCBI chr 7:131,992,151...131,996,850
Ensembl chr 7:131,968,770...131,996,035

G

tuftelin 1

increases expression

ISO

belinostat results in increased expression of TUFT1 mRNA

NCBI chr 2:184,949,437...184,995,321
Ensembl chr 2:184,949,437...184,995,383

G

twist family bHLH transcription factor 1

increases expression

ISO

belinostat results in increased expression of TWIST1 protein

NCBI chr 6:50,674,910...50,676,904
Ensembl chr 6:56,398,061...56,404,965

G

thioredoxin reductase 3

decreases expression

ISO

belinostat results in decreased expression of TXNRD3 mRNA

NCBI chr 4:122,072,548...122,112,493
Ensembl chr 4:123,648,750...123,668,552

G

thymidylate synthetase

decreases expression

ISO

belinostat results in decreased expression of TYMS mRNA

NCBI chr 9:120,760,057...120,776,149
Ensembl chr 9:120,763,386...120,776,097

G

UDP glucuronosyltransferase family 1 member A1

decreases glucuronidation
increases glucuronidation
multiple interactions

ISO

UGT1A1 gene polymorphism results in decreased glucuronidation of belinostat
UGT1A1 protein results in increased glucuronidation of belinostat
belinostat inhibits the reaction [[UGT1A1 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide]; belinostat inhibits the reaction [UGT1A1 protein results in increased glucuronidation of Hymecromone]

PMID:23382909 PMID:33290829

NCBI chr 9:96,249,143...96,256,264
Ensembl chr 9:96,144,786...96,256,264

G

UDP glucuronosyltransferase 1 family, polypeptide A2

multiple interactions

ISO

belinostat inhibits the reaction [[UGT1A3 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide]; belinostat inhibits the reaction [UGT1A3 protein results in increased glucuronidation of Hymecromone]

NCBI chr 9:88,791,216...88,808,465
Ensembl chr 9:96,144,786...96,256,264

G

UDP glucuronosyltransferase family 1 member A6

multiple interactions

ISO

belinostat inhibits the reaction [[UGT1A6 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide]; belinostat inhibits the reaction [UGT1A6 protein results in increased glucuronidation of Hymecromone]

NCBI chr 9:88,747,213...88,808,465
Ensembl chr 9:96,144,786...96,256,264

G

UDP glucuronosyltransferase family 2 member B7

multiple interactions

ISO

belinostat inhibits the reaction [[UGT2B7 protein results in increased glucuronidation of Hymecromone] which results in increased chemical synthesis of 4-methylumbelliferyl glucuronide]; belinostat inhibits the reaction [UGT2B7 protein results in increased glucuronidation of Hymecromone]

NCBI chr14:20,896,682...20,919,604
Ensembl chr14:21,251,535...21,274,451

G

UDP glycosyltransferase family 3 member A1

increases expression
multiple interactions

ISO

belinostat results in increased expression of UGT3A1 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT3A1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:58,327,058...58,350,186
Ensembl chr 2:60,061,775...60,077,354

G

UDP glycosyltransferase 8

increases expression
multiple interactions

ISO

belinostat results in increased expression of UGT8 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UGT8 mRNA

PMID:26272509 PMID:27188386

NCBI chr 2:214,264,483...214,332,769
Ensembl chr 2:216,938,990...217,007,167

G

unc-93 homolog A

decreases expression

ISO

belinostat results in decreased expression of UNC93A mRNA

NCBI chr 1:52,973,143...53,029,578
Ensembl chr 1:55,528,281...55,549,768

G

uracil-DNA glycosylase

decreases expression

ISO

belinostat results in decreased expression of UNG mRNA

NCBI chr12:42,485,276...42,494,217
Ensembl chr12:48,145,838...48,155,257

G

ubiquitin specific peptidase 28

increases expression
multiple interactions

ISO

belinostat results in increased expression of USP28 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of USP28 mRNA

PMID:26272509 PMID:27188386

NCBI chr 8:49,325,766...49,386,229
Ensembl chr 8:58,222,220...58,282,750

G

undifferentiated embryonic cell transcription factor 1

multiple interactions
increases expression

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of UTF1 mRNA
belinostat results in increased expression of UTF1 mRNA

PMID:26272509 PMID:27188386

NCBI chr 1:194,740,339...194,741,465
Ensembl chr 1:204,169,954...204,171,080

G

urotensin 2B

decreases expression

ISO

belinostat results in decreased expression of UTS2B mRNA

NCBI chr11:73,424,385...73,439,429
Ensembl chr11:86,929,210...86,944,255

G

vasohibin 2

increases expression
multiple interactions

ISO

belinostat results in increased expression of VASH2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VASH2 mRNA

PMID:26272509 PMID:27188386

NCBI chr13:102,529,718...102,561,204
Ensembl chr13:105,060,857...105,092,275

G

VENT homeobox

increases expression
multiple interactions

ISO

belinostat results in increased expression of VENTX mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VENTX mRNA

PMID:26272509 PMID:27188386

NCBI chr X:86,483,893...86,484,900
Ensembl chr X:90,706,748...90,708,555

G

ventricular zone expressed PH domain-containing 1

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of VEPH1 mRNA

NCBI chr 2:150,291,379...150,537,491
Ensembl chr 2:152,601,680...152,847,318

G

vimentin

increases expression
multiple interactions

ISO

belinostat results in increased expression of VIM protein
pyrvinium inhibits the reaction [belinostat results in increased expression of VIM protein]

NCBI chr17:81,577,261...81,585,746
Ensembl chr17:81,568,272...81,585,746

G

WAP four-disulfide core domain 2

increases expression
multiple interactions

ISO

belinostat results in increased expression of WFDC2 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WFDC2 mRNA

PMID:26272509 PMID:27188386

NCBI chr 3:153,286,946...153,314,832
Ensembl chr 3:173,706,460...173,712,161

G

Wnt inhibitory factor 1

decreases expression

ISO

belinostat results in decreased expression of WIF1 mRNA

NCBI chr 7:56,548,060...56,618,364
Ensembl chr 7:58,384,643...58,503,852

G

Wnt family member 3A

increases expression

ISO

belinostat results in increased expression of WNT3A mRNA

NCBI chr10:44,533,734...44,577,919
Ensembl chr10:44,533,734...44,577,919

G

Wnt family member 4

increases expression
multiple interactions

ISO

belinostat results in increased expression of WNT4 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of WNT4 mRNA

PMID:23671600 PMID:26272509 PMID:27188386

NCBI chr 5:154,797,245...154,818,565
Ensembl chr 5:154,797,311...154,817,128

G

Wnt family member 5B

decreases expression

ISO

belinostat results in decreased expression of WNT5B mRNA

NCBI chr 4:152,609,566...152,733,790
Ensembl chr 4:154,281,852...154,405,681

G

Wnt family member 7B

increases expression

ISO

belinostat results in increased expression of WNT7B mRNA

NCBI chr 7:118,514,684...118,559,316
Ensembl chr 7:118,514,684...118,559,316

G

WW domain containing transcription regulator 1

multiple interactions

ISO

belinostat results in decreased degradation of and results in increased stability of and results in increased expression of WWTR1 protein; pyrvinium inhibits the reaction [belinostat results in increased expression of WWTR1 protein]

NCBI chr 2:141,651,159...141,766,919
Ensembl chr 2:143,801,181...143,991,950

G

XK related 6

increases expression

ISO

belinostat results in increased expression of XKR6 mRNA

NCBI chr15:37,857,096...38,059,699
Ensembl chr15:42,033,028...42,235,591

G

X-ray repair cross complementing 1

decreases expression

ISO

belinostat results in decreased expression of XRCC1 mRNA; belinostat results in decreased expression of XRCC1 protein

NCBI chr 1:89,268,721...89,296,619
Ensembl chr 1:89,268,644...89,296,613

G

Yes1 associated transcriptional regulator

multiple interactions

ISO

belinostat results in decreased expression of and results in decreased phosphorylation of YAP1 protein

NCBI chr 8:13,380,551...13,451,640
Ensembl chr 8:13,380,551...13,451,437

G

zinc finger and BTB domain containing 1

decreases expression

ISO

belinostat results in decreased expression of ZBTB1 mRNA

NCBI chr 6:95,096,838...95,125,811
Ensembl chr 6:100,838,714...100,852,643

G

zinc finger and BTB domain containing 38

decreases expression

ISO

belinostat results in decreased expression of ZBTB38 mRNA

NCBI chr 8:97,284,617...97,288,518
Ensembl chr 8:106,157,084...106,230,951

G

zinc finger E-box binding homeobox 1

multiple interactions

ISO

[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in decreased expression of ZEB1 mRNA

NCBI chr17:56,644,397...56,811,155
Ensembl chr17:56,644,397...56,810,745

G

zinc finger protein 185

decreases expression

ISO

belinostat results in decreased expression of ZNF185 mRNA

NCBI chr X:150,831,869...150,877,652
Ensembl chr X:155,874,127...155,917,077

G

zinc finger protein 266

increases expression

ISO

belinostat results in increased expression of ZNF562 mRNA

NCBI chr 8:19,030,766...19,061,381
Ensembl chr 8:27,307,015...27,320,143

G

zinc finger protein 36

decreases expression

ISO

belinostat results in decreased expression of ZFP36 mRNA

NCBI chr 1:83,669,084...83,671,564
Ensembl chr 1:92,796,628...92,799,108

G

zinc finger protein 397

increases expression

ISO

belinostat results in increased expression of ZNF397 mRNA

NCBI chr18:15,241,764...15,253,148
Ensembl chr18:15,516,775...15,525,219

G

zinc finger protein 42

increases expression
multiple interactions

ISO

belinostat results in increased expression of ZFP42 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP42 mRNA

PMID:26272509 PMID:27188386

NCBI chr16:48,836,463...48,845,443
Ensembl chr16:55,568,093...55,578,170
Ensembl chr 4:55,568,093...55,578,170

G

Zic family member 3

increases expression
multiple interactions

ISO

belinostat results in increased expression of ZIC3 mRNA
[NOG protein co-treated with belinostat co-treated with dorsomorphin co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZIC3 mRNA

PMID:26272509 PMID:27188386

NCBI chr X:141,159,623...141,165,587
Ensembl chr X:141,149,594...141,170,464

G

zinc finger, matrin type 3

increases expression

ISO

belinostat results in increased expression of ZMAT3 mRNA

NCBI chr 2:115,106,046...115,136,888
Ensembl chr 2:117,034,517...117,065,294

G

zinc finger MYM-type containing 6

decreases expression

ISO

belinostat results in decreased expression of ZMYM6 mRNA

NCBI chr 5:139,396,374...139,444,357
Ensembl chr 5:144,681,197...144,728,803

G

zinc finger protein 750

increases expression

ISO

belinostat results in increased expression of ZNF750 mRNA

NCBI chr10:106,772,162...106,781,186
Ensembl chr10:107,270,763...107,279,300

Term paths to the root

Path 1
Term	Annotations
CHEBI ontology	20862
role	20820
application	20621
pharmaceutical	20416
drug	20416
antineoplastic agent	18066
belinostat	654
Path 2
Term	Annotations
CHEBI ontology	20862
subatomic particle	20860
composite particle	20860
hadron	20860
baryon	20860
nucleon	20860
atomic nucleus	20860
atom	20860
main group element atom	20781
p-block element atom	20781
carbon group element atom	20715
carbon atom	20710
organic molecular entity	20710
heteroorganic entity	20219
organochalcogen compound	19904
organooxygen compound	19806
carbon oxoacid	19155
carboxylic acid	19152
carboacyl group	18085
univalent carboacyl group	18085
carbamoyl group	17921
carboxamide	17921
hydroxamic acid	6350
belinostat	654

paths to the root